Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
08/2011 | Recent  |  14:  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions August inventions list 08/11

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
08/25/2011 > patent applications in patent subcategories. inventions list

20110207653 - Microparticle encapsulated thiol-containing polypeptides together with a redox reagent: The present invention relates to polymeric microparticles comprising a therapeutic polypeptide along with a redox reagent. Also disclosed are methods of using the microparticles, including methods of using the microparticles for delivery of the therapeutic polypeptide to a subject in need thereof.... Agent:

20110207654 - Peptide analogues: e

20110207655 - Cyclic depsipeptide compound and use thereof: [Means for Solution]The present inventors have made extensive studies on the pharmacological actions of naturally fermented materials, and as a result, they have found that a cyclic depsipeptide compound derived from a soil bacterium belonging to the genus Chromobacterium which is collected in Okutama-machi, Tokyo has both an inhibitory action... Agent: Astellas Pharma Inc.

20110207656 - Muc1, caspase-8, and ded-containing proteins: The disclosure features a variety of compositions and methods for modulating an interaction between MUC1 and caspase-8 and/or an interaction between MUC1 and a DED-containing protein (e.g., an anti-apoptotic DED-containing protein or a pro-apoptotic DED-containing protein). Such methods and compositions are useful for the treatment or prevention of, e.g., a... Agent: Dana-farber Cancer Institute, Inc.

20110207657 - Selectively targeted antimicrobial peptides and the use thereof: The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., P. aeruginosa or S. mutans), antimicrobial peptides having antimicrobial activities, and specifically/selectively targeted antimicrobial peptides (STAMPs). In addition, the present invention provides methods of selectively killing or inhibiting microbial organisms by using the peptides or... Agent:

20110207658 - High purity lipopeptides: The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion... Agent:

20110207659 - Oligosaccharide compositions and use thereof in the treatment of infection: Oligosaccharides and oligosaccharides linked to backbones such as proteins, methods for making such oligosaccharides and methods for using them to treat and/or prevent various disorders are described.... Agent: Instituto Nacional De Ciencias Medicas Y Nutricion

20110207660 - Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion: The present invention provides pharmaceutical formulations of an HCV protease inhibitor in a solid dispersion with an excipient which provided advantageous pharmacokinetic properties for inhibiting or treating HCV infection. In preferred embodiments, the excipient is at least one polymer. The present invention also provides processes for manufacturing such formulations as... Agent: Schering Corporation

20110207661 - Benzylbenzene derivatives and methods of use: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.... Agent: Theracos, Inc.

20110207662 - Composition for long-acting peptide analogs: The invention describes compositions of peptide analogs that are active in blood or cleavable in blood to release an active peptide. The peptide analogs have a general formula: A-(Cm)x-Peptide (SEQ ID NO: 76), wherein A is hydrophobic moiety or a metal binding moiety, e.g., a chemical group or moiety containing... Agent: Pharmain Corporation

20110207663 - Fibroblast growth factor (fgf) analogs and uses thereof: The invention relates to novel peptide comprising FGF-P and methods of use thereof.... Agent: University Of Rochester

20110207664 - Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins: The present invention provides polypeptides that bind cellular receptors for vascular endothelial growth factor polypeptides; polynucleotides encoding such polypeptides; compositions comprising the polypeptides and polynucleotides; and methods and uses involving the foregoing. Some polypeptides of the invention exhibit unique receptor binding profiles compared to known, naturally occurring vascular endothelial growth... Agent: Vegenics Pty Limited

20110207665 - Method of regulating proliferation and differentiation of keratinocyes: Provided are methods of regulating keratinocytes proliferation and differentiation by subjecting keratinocytes to an agent capable of modulating activity or expression of IGFBP7, thereby regulating keratinocytes proliferation and differentiation. Also provided are methods of treating pathologies characterized by hyperproliferative keratinocytes by administering IGFBP7 polypeptide or a polynucleotide encoding IGFBP7 polypeptide... Agent: Rappaport Family Institute For Research In The Med

20110207666 - Method of promoting bone growth with hyaluronic acid and growth factors: A bone growth-promoting composition is provided comprising hyaluronic acid and a growth factor. The composition has a viscosity and biodegradability sufficient to persist at an intra-articular site of desired bone growth for a period of time sufficient to promote the bone growth. Preferably hyaluronic acid is used in a composition... Agent: Depuy Spine, Inc.

20110207668 - Binding proteins inhibiting the vegf-a receptor interaction: The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity. The binding proteins are useful in... Agent: Molecular Partners Ag

20110207667 - Efficient expression of truncated human rnaset2 in e. coli: An isolated, recombinant truncated human RNASET2 having anti-angiogenic properties, methods for efficient expression thereof in bacteria and therapeutic uses thereof.... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.

20110207669 - Recombinant proteins having haemostatic activity and capable of inducing platelet aggregation: Disclosed herein are recombinant proteins capable of inducing platelet aggregation and uses thereof.... Agent: Centre Hospitalier Universitaire De Dijon

20110207670 - Compositions and methods of use for soluble thrombomodulin variants: The present invention provides a method for preventing and/or treating a patient with acute kidney injury caused by a variety of conditions. The method comprises administering to the patient soluble thrombomodulin variants that do not bind thrombin. In conjunction with standard of care, soluble thrombomodulin variants that do not bind... Agent: Eli Lilly And Company

20110207671 - Method for producing double-crosslinked collagen: The present invention relates to double-crosslinked collagen materials, methods for preparing double-crosslinked collagen materials, and methods of using double-crosslinked... Agent: Fibrogen, Inc.

20110207672 - Methods of treatment using a prodrug of an excitatory amino acid: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.... Agent: Eli Lilly And Company

20110207675 - Gene fusion targeted therapy: The present invention relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present invention relates to recurrent gene fusions as clinical targets for prostate cancer.... Agent: The Regents Of The University Of Michigan

20110207676 - Glycosylation of molecules: Described herein are methods and genetically engineered cells useful for producing an altered N-glycosylation form of a target molecule. Also described are methods and molecules with altered N-glycosylation useful for treating a variety of disorders such as metabolic disorders.... Agent:

20110207673 - Methods and compositions for modulating drug-polymer architecture, pharmacokinetics and biodistribution: Drug-polymer chemotherapeutics are provided having improved therapeutic efficacy and reduced dose-limiting toxicity. Methods are also provided for modulating the architecture, pharmacokinetics and biodistribution of drug-polymers and for reducing the dependence of transition temperature on concentration for drug-polymers.... Agent:

20110207674 - Antitumoral compounds: u

20110207678 - Cd44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases: An isolated polypeptide is provided. The isolated polypeptide comprising an antigen recognition domain capable of specifically binding a CD44 polypeptide as set forth in SEQ ID NO: 2 and incapable of binding a CD44 polypeptide selected from the group consisting of: SEQ ID NO: 4 or 6.... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem

20110207677 - Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of non-chronic... Agent:

20110207679 - Methods of treatment using il-16 antagonist peptides: The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acid in length. Based on... Agent: Trustees Of Boston University

20110207680 - Administration of glufosfamide for the treatment of cancer: Administration of Glufosfamide alone and in combination with another anticancer agent is useful for the treatment of gall bladder cancer.... Agent:

20110207682 - Pharmaceutical composition useful for the treatment of peptic ulcer diseases: The present invention deals with the pharmaceutical composition comprising the therapeutically effective amount of a compound oenothein C obtained from the bioactive fraction of plant Woodfordia fruticosa optionally along with one or more pharmaceutically acceptable carriers, additives, lubricants and diluents. Further it also provides a method of treating peptic ulcer... Agent: Council Of Scientific And Industrial Research

20110207681 - Use of glucosylglycerol: The invention relates to the use of glucosylglycerol or glucosylglycerol esters with a view to increasing the expression of cell protective enzymes for the protection and stabilization of human skin and/or mucous membranes. It has been demonstrated that glucosylglycerol plays an effective role in the stimulation and activation of cell... Agent:

20110207683 - Natural colorant and methods thereof: To provide a material composed mainly of a material derived from dragon fruit having to provide a supplement, a drug, a cosmetic or a food produced by using the material. The invention provides a material derived from dragon fruit, especially, a powder of dragon fruit, and a supplement, a drug,... Agent: University Putra Malaysia

20110207684 - New low side effect pharmaceutical composition containing isoniazid: The present invention features a novel, low side-effect pharmaceutical compound complex, comprising the pharmaceutically effective dose of isoniazid (INH) and pharmaceutically effective dose of one of the following compounds. Said compound was selected from the following groups of compounds: Nordihydroguaiaretic acid, Trans-Cinnamaldehyde, Daidzein, Isovitexin, Kaempferol, disulfuram, β-Myrcene, Quercetin, (−)-Epigallocatechin-3-gallate, (+)-Limonene,... Agent:

20110207685 - Oral formulations of chemotherapeutic agents: The present invention is directed to new oral formulations of chemotherapeutic agents, their process of preparation as well as their therapeutic uses. More specifically, said invention is related to nanoparticles comprising at least one chemotherapeutic agents as an active ingredient, at least one polymer and at least one cyclic oligosaccharide... Agent:

20110207686 - Polysaccharide-and polypeptide-based block copolymers, vesicles constituted by these copolymers and use thereof: The invention relates to a new type of polysaccharide-block-polypeptide diblock copolymer which is bioresorbable or biodegradable and biocompatible, to a method for preparing same, to the micellar vesicles constituted of this copolymer, and to the use thereof for encapsulation, transport, vectorization, and targeting of molecules of interest.... Agent: Institut Polytechnique De Bordeaux

20110207687 - Fulvic acid and antibiotic combination: This invention relates to a fulvic acid and antibiotic combination for use in the treatment of various diseases and conditions. The invention further relates to the use of the combination for the treatment of various diseases and conditions, including bacterial infection. In particular, the bacteria are antibiotic resistant bacteria.... Agent: Pfeismith S.a. (pty) Ltd

20110207796 - Alpha-synuclein kinase: Agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient are provided. Preferred agents include inhibitors of PLK2 kinase.... Agent: Elan Pharma International Limited

20110207799 - Compositions for targeted delivery of sirna: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification... Agent: Roche Madison Inc.

20110207797 - Enhanced antisense oligonucleotides: Described herein are gap-widened antisense oligonucleotides having improved therapeutic index as compared to 5-10-5 MOE gapmer antisense oligonucleotides of the same sequence. Also described are methods of reducing a target RNA in an animal using the gap-widened antisense oligonucleotides of the present invention. Further, are methods for selecting a gap-widened... Agent: Isis Pharmaceuticals, Inc.

20110207798 - Method for treating breast cancer using adenine nucleotide translocator 2 (ant2) sirna or ant2 shrna: The present invention relates to adenine nucleotide translocator 2 (ANT2) siRNA (small interfering RNA) or ANT2 shRNA (short hairpin RNA) suppressing the expression of ANT2 gene expression and anticancer agent containing the same. Furthermore, the present invention relates to methods for treating breast cancers or stem cells of a breast... Agent: Bioinfra Inc.

20110207795 - Smad7 inhibitor compositions and uses thereof: The present invention relates to the use of a specific inhibitor of Smad7 expression or function for the preparation of a pharmaceutical composition for the prevention, amelioration or treatment of a disease of the central nervous system and/or diseases related and/or caused by said disease of the central nervous system.... Agent:

20110207802 - Glutamic acid decarboxylase (gad) based delivery system: The invention provide methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain that is overstimulated in neurodegenerative diseases. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding... Agent: Neurologix, Inc.

20110207800 - Hiv-dependent expression constructs and uses therefore: The invention provides a nucleic acid construct for targeting and killing cells infected with the human immunodeficiency virus (HIV). The construct includes an HIV Tat-dependent promoter operably linked to the coding region for a cell-killing protein, such as anthrolysin-O (anlO), which is partially or fully within an intron defined by... Agent:

20110207801 - Novel genes, compositions, and methods for modulating the unfolded protein response: The present invention relates to methods and compositions for modulating the unfolded protein response. The method further relates to methods and compositions for the treatment and diagnosis of protein conformational diseases or disorders, including, but not limited to, α1-antitrypsin deficiency, cystic fibrosis, and autoimmune diseases and disorders. The invention further... Agent: University Of Michigan

20110207688 - Heterocyclic antiviral compounds: The present invention relates to a method of treating an HIV-I infection with a compound according to formula I where R1, R2, R3, R4, R5, are as defined herein.... Agent:

20110207689 - The treatment of hearing loss: The invention provides a method of treating noise-induced hearing loss, the method including the step of administering an A1 adenosine receptor agonist to a patient in need thereof. In a particularly preferred embodiment the A1 adenosine receptor agonist is a selective A1 adenosine receptor agonist.... Agent: Auckland Uniservices Limited

20110207691 - Cobalamin compositions for the treatment of cancer: Compositions are provided that contain a combination of a nitric oxide-cobalamin complex along with at least one cobalamin drug conjugate, together with methods for their use in the treatment of neoplastic disease.... Agent: Bebaas, Inc.

20110207690 - Compositions and methods for treating viral infections: m

20110207692 - Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine: A first aspect of the invention relates to a combination comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof. A second aspect of the invention relates to a pharmaceutical product comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, as a combined preparation for... Agent: Cyclacel Limited

20110207693 - Oral b12 therapy: Methods of normalizing vitamin B12 levels in patients with low vitamin B12 and methods of normalizing intersubject variability in the treatment of such patients are described. Methods of reducing MMA and/or homocysteine levels, and pharmaceutical compositions useful to effect such changes are also described.... Agent: Emisphere Technologies, Inc.

20110207694 - Mammalian hypothalamic nutrient modulation of glucose metabolism: Provided are methods of reducing glucose production in a mammal, methods of reducing food intake in a mammal, methods of inhibiting gluconeogenesis in the liver of a mammal, methods of reducing peripheral blood glucose levels in a mammal, methods of decreasing serum triglyceride levels in a mammal, and methods of... Agent:

20110207695 - Agent for applying to mucosa and method for the production thereof: An agent for applying to mucosa capable of persistently exerting a therapeutic effect on disorders such as inflammation and lesions in the mucosa even by a lower frequency of administration because the agent can stay at a diseased site for a long period of time by exhibiting a high staying... Agent: Seikagaku Corporation

20110207696 - Compositions for treating rosacea: The present invention is directed to compositions containing chitosan, a chitosan derivative or a physiologically acceptable salt thereof, and a short-medium chain dicarboxylic acid amide, or a physiologically acceptable salt thereof, forming a film after application onto the skin, useful for protecting skin of the face and of other affected... Agent: Polichem Sa

20110207697 - Xanthohumol compositions and methods for treating skin diseases or disorders: The present invention features therapeutic and prophylactic compositions comprising xanthohumol and/or xanthohumol/cyclodextrin complexes and methods of using such compositions for treating a skin condition, disease, or disorder.... Agent: Betal, LLC

20110207699 - Anti-viral compounds: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.... Agent: Abbott Labaoratories

20110207698 - Heteroaryl-substituted dicyanopyridines and their use: The present application relates to novel heteroaryl-substituted dicyanopyridines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular disorders.... Agent: Bayer Schering Pharma Aktiengesellschaft

20110207700 - Tricyclic compound and use thereof: (wherein, all the symbols have the same meaning as that of the specification), a salt thereof, a solvate thereof or a prodrug thereof. Since the compound of the present invention has an anti stress action, it is useful for preventive and/or therapeutic agent for a disease caused by stress, especially... Agent: Ono Pharmaceutical Co., Ltd.

20110207702 - Boron-containing small molecules as anti-protozoal agents: This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.... Agent: Anacor Pharmaceuticals, Inc.

20110207701 - Boron-containing small molecules as antiprotozoal agents: This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.... Agent: Anacor Pharmaceuticals, Inc.

20110207703 - Oxidized lipid compounds and uses thereof: Novel oxidized lipids are provided herein, as well as methods for producing same, and uses thereof in treating or preventing an inflammation associated with endogenous oxidized lipids and related conditions.... Agent: Vascular Biogenics Ltd.

20110207704 - Novel oxadiazole compounds: Novel oxadiazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions as agonists or antagonists of the S1P family of G protein-coupled receptors for treating diseases associated with modulation of S1P family receptor activity, in particular by affording a beneficial immunosuppressive effect are disclosed.... Agent: Abbott Laboratories

20110207706 - Methods for treating spinal muscular atrophy using tetracycline compounds: Methods for using tetracycline compounds for the treatment of spinal muscular atrophy are described.... Agent: Paratek Pharmaceuticals, Inc.

20110207705 - Oviedomycin derivatives, method for obtaining same and use thereof: Oviedomycin derivatives, method for obtaining same and use thereof. This invention relates to oviedomycin derivatives obtained by fermentation of recombinant bacterial strains. The invention also relates to the methods used to obtain the recombinant strains and to produce the oviedomycin derivatives. The invention further relates to bacterial strains that can... Agent: Universidad De Oviedo

20110207708 - Androgen treatment in females: The present invention is directed to a method of using dehydroepiandrosterone to treat a human female with diminished ovarian reserve. The method includes administering about 25 milligrams three times a day of dehydroepiandrosterone per day to the female for at least four weeks to reduce human embryo aneuploidy. The present... Agent:

20110207707 - Compounds that act to modulate insect growth and methods and systems for identifying such compounds: Disclosed are methods and systems for screening for compounds that act to modulate insect growth. Bioassays including cell culture and/or transgenic insects engineered with various components of the ecdysoid receptor (EcR) and/or the farsenoid-X receptor (RXR) systems to identify compounds that act as insecticides and/or hormone receptor activators are described.... Agent:

20110207709 - Modulators of serotonin receptor: Certain biphenyl compounds are serotonin modulators useful in the treatment of serotonin-mediated diseases.... Agent:

20110207710 - Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase a2 (spla2) inhibitors and spla2 inhibitor combination therapies: Administration of sPLA2 inhibitors has been found to decrease cholesterol levels, atherosclerotic plaque formation and aortic aneurysm in mice, and to decrease cholesterol and triglyceride levels in humans. Interestingly, administration of sPLA2 inhibitors was found to decrease cholesterol levels even when the inhibitors were administered only once per day. Therefore,... Agent:

20110207711 - Therapeutic compounds: The present invention relates to pyrazolopyridines and imidazopyridines which are inhibitors of the kinase PDK1 and are thus useful for the treatment of myeloproliferative disorders or cancer. The compounds are also useful as inhibitors of other kinases such as FGFR3, NTRK3, RP-S6K and WEE1. Furthermore, the present compounds also selectively... Agent:

20110207712 - Phosphatidylinositol 3-kinase inhibitors and methods of their use: The present invention comprises small molecule inhibitors of phosphatidylinositol 3-kinase (PI3K), which is associated with a number of malignancies such as ovarian cancer, cervical cancer, breast cancer, colon cancer, rectal cancer, and glioblastomas, among others. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting these... Agent: Exelixis, Inc.

20110207713 - Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use: Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ,... Agent:

20110207714 - Serotonin receptor modulators: The biphenyic compounds of formula (I) are serotonin modulators useful in the treatment of serotonin-mediated diseases.... Agent:

20110207715 - Disubstituted azepan orexin receptor antagonists: The present invention is directed to disubstituted azepan and oxazepan amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these... Agent:

20110207716 - Inhibitors of polo-like kinase: or a salt or solvate thereof, wherein ring A, E1, E2, R1, R2, R3 and R4 are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention... Agent: Elan Pharmaceuticals, Inc.

20110207717 - 2-aminopyrimidine compounds as serotonin receptor modulators: Certain 2-aminopyrimidine compounds are serotonin receptor modulators useful in the treatment of diseases mediated by serotonin receptors.... Agent:

20110207718 - Compositions and methods for treating psychiatric disorders: Methods of treating psychiatric disorders are provided which include administration of one or more anti-epileptic agents and, optionally, one or more a psychostimulants. Also provided are pharmaceutical compositions comprising, in combination, one or more anti-epileptic agents and one or more psychostimulants. Psychiatric disorders include those associated with impaired cognitive processing,... Agent: Gosforth Centre (holdings) Pty Ltd.

20110207719 - Novel anthra [1, 2-d]imidazole-6,11-dione derivatives, preparation method and application thereof: A series of novel anthra[1,2-d]imidazole-6,11-dione derivatives, and the preparation method and application of said derivatives, wherein said application includes a pharmaceutical composition containing said derivatives for treating cancer, and said application involves effects of said derivatives for inhibiting telomerase activity, inhibiting the growth of cancer cell, treating cancer and the... Agent:

20110207720 - Quinolin-4-one and 4-oxodihyrdocinnoline derivatives as inhibitors of poly(adp-ribose) polymerase (parp): The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative... Agent:

20110207721 - Purine derivatives as kinase inhibitors: The present invention provides kinase inhibitors of Formula I.... Agent: Eli Lilly And Company

20110207722 - Treatment of anxiety disorders: This invention relates to the treatment of anxiety disorders. The invention furthermore relates to novel pharmaceutical compositions comprising a therapeutically effective amount of the compound exo-7-(8-H-8-aza-bicyclo[3.2.1]oct-3-yloxy)-chromen-2-one, or a therapeutically effective amount of the compound exo- 7-(8-H-8- aza-bicyclo[3.2.1]oct-3-yloxy)-chromen-2-one and a benzodiazepine drug.... Agent: Neurosearch A/s

20110207723 - Novel fused aminodihydrothiazine derivative: a pharmaceutically acceptable salt thereof, or a solvate of the compound or salt has an Aβ production inhibitory activity or BACE 1 inhibitory activity, and is thus useful as an agent for treating neurodegenerative diseases caused by Aβ as typified by Alzheimer's disease. In the formula, ring A represents a... Agent: Eisai R&d Management Co., Ltd.

20110207724 - Pharmaceutical formulations and methods of use which combine non-steroidal anti-inflammatory compounds with anit-hypertensive compounds: An oral dosage form of a non-steroidal anti-inflammatory drug (NSAID) is rendered safer for extended or chronic use for anti-inflammatory, analgesic or antipyretic therapy by combining it with an antihypertensive drug. The antihypertensive drug acts prophylactically to inhibit or reduce NSAID-induced hypertension and by so doing the adverse cardiovascular side... Agent:

20110207725 - Chiral fused [1,2]imidazo[4,5-c] ring compounds: Fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—X1—R1)-group in the fused ring at the 1-position of the imidazo ring, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals... Agent: 3m Innovative Properties Company

20110207726 - Inhibitors of human cathepsin l, cathepsin b, and cathepsin s: The present invention is directed to novel protease inhibitors that are specific for cathepsin L, cathepsin B, and cathepsin S. Accordingly, the present invention encompasses compositions and methods for treating and preventing diseases and disorders associated with cathepsin L, cathepsin B, or cathepsin S function or activity.... Agent: The Trustees Of The University Of Pennsylvania

20110207727 - Thio-subsituted anthra [1, 2-d] imidazole- 6, 11-dione dervatives, preparation method and application thereof: A series of novel thio-substituted anthra[1,2-d]imidazole-6,11-dione dervatives, and the preparation method and application of said derivatives, said application having a pharmaceutical composition containing said derivatives with therapeutically effective amount for treating cancer, and said application involves effects of said derivatives for inhibiting telomerase activity, inhibiting the growth of cancer cell,... Agent:

20110207728 - Compounds for treating respiratory syncytial virus infections: s

20110207729 - Bicyclic acylguanidine derivative: It was confirmed that a bicyclic acylguanidine derivative which has a characteristic structure that guanidine is bonded to one ring of a bicyclic structure such as chromene and dihydronaphthalene through a carbonyl group and a cyclic group is bonded on the other ring, has a potent 5-HT5A receptor modulating action... Agent: Astellas Pharma Inc.

20110207730 - Ion channel modulating compounds and uses thereof: Ion channel modulating compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment of arrhythmia and the production of analgesia and local... Agent: Cardiome Pharma Corp.

20110207732 - Azaindole derivatives: Compounds of the formula (I), in which X1, X2, X3, X4, R1, R2, R3 and R4 have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20110207731 - Substituted 4-(indazolyl)-1,4-dihydropyridines and methods of use thereof: This invention relates to novel 4-(indazolyl)-1,4-dihydropyridine og the following formula (I) derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.... Agent: Bayer Schering Pharma Aktiengesellschaft

20110207734 - Azine derivatives and methods of use thereof: The present invention relates to Azine Derivatives, pharmaceutical compositions comprising the Azine Derivatives and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes,... Agent:

20110207735 - Cyanopyrimidinones: The invention relates to novel cyanopyrimidinones, process for their preparation, and the use thereof for producing medicaments for improving perception, concentration, learning and/or memory.... Agent:

20110207733 - Pyrimidine derivatives for treatment of alzheimer's disease: The invention encompasses pyrimidine derivatives as gamma secretase modulators, useful for treating diseases associated with the deposition of beta-amyloid peptide in the brain, such as Alzheimer's disease, or of preventing or delaying the onset of dementia associated with such diseases. Pharmaceutical compositions and methods of use are included.... Agent:

20110207736 - Compounds that modulate egfr activity and methods for treating or preventing conditions therewith: Provided are compounds and methods for treating or preventing kinase-mediated disorders therewith.... Agent: Gatekeeper Pharmaceuticals, Inc.

20110207737 - Substituted bicyclic amines for the treatment of diabetes: Described herein are substituted bicyclic amines. In particular, described herein are substituted bicyclic amines that are effective as antagonists of SSTR5 and useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, metabolic syndrome, depression,... Agent: Merck Sharp & Dohme Corp

20110207738 - Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals: The invention relates to annelated pyrrolidin sulfonamides with oxadiazolone headgroup and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta or PPARdelta and PPARalpha agonist activity. What is described are compounds of the formula (I), in which the radicals are as defined, and their physiologically acceptable salts and... Agent: Sanofi-aventis

20110207739 - Novel 1, 2-disubstituted amido-anthraquinone derivatives, preparation method and application thereof: A series of novel 1,2-disubstituted amido-anthraquinone derivatives, and the preparation method and application of said derivatives. Said application includes said derivatives with therapeutically effective amount being prepared into pharmaceutical compositions for inhibition of cancer cell growth, further treating cancer.... Agent:

20110207740 - Pharmaceutical compositions: Disclosed are useful pharmaceutical compositions.... Agent:

20110207741 - Activation of the renin-angiotensin system (ras) and sudden cardiac death: Provided herein are methods of treating a medical condition in which RAS activation is increased. The method comprises the step of administering to a subject a c-Src inhibitor in an amount effective to treat the medical condition. The invention also provides a method of treating or preventing a cardiac arrhythmia.... Agent: The Board Of Trustees Of The University Of Illinois

20110207742 - Method for reduction, stabilization and prevention of rupture of lipid rich plaque: There is to provide is an agent for reduction of a lipid rich plaque, stabilization of a lipid rich plaque and/or prevention of rupture of a lipid rich plaque in an atherosclerotic lesion comprising an effective amount of 2-[4-[2-(benzimidazole-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-p yridyl]acetamide (hereinafter, referred to as compound 1), its pharmaceutically acceptable salt... Agent: Kowa Co., Ltd.

20110207743 - Pyrazolylaminopyridines as inhibitors of fak: e

20110207744 - Method for treating cognitive deficits: The invention relates to methods of treating cognitive dysfunction and improving cognitive functioning comprising the administration of trans-4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine or a pharmaceutically acceptable salt thereof to a patient in need thereof. Moreover the invention relates to an improved binder in a composition comprising 4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine.... Agent: H. Lundbeck A/s

20110207745 - Solid forms of 4--n,n-diethylbenzamide, compositions thereof, and uses therewith: Solid forms comprising salts of 4-{(R)-(3-aminophenyl)[4-(4-fluorobenzyl)piperazin-1-yl]methyl}-N,N-diethylbenzamide, compositions comprising the solid forms, methods of making the solid forms, and methods of their use for the treatment of various diseases and/or disorders are provided herein.... Agent: Astrazeneca Ab

20110207747 - 2,5-disubstituted phenyl carboxamide orexin receptor antagonists: The present invention is directed to 2,5-disubstituted phenyl carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and... Agent:

20110207746 - New compounds i: and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial,... Agent: Proximagen Limited

20110207750 - Benzimidazole and aza-benzimidazole carboxamides: This invention provides compounds of Formula I which are PAFR antagonists: I and the pharmaceutically acceptable salts thereof. The compounds are useful for treating PAF-mediated disorders, and can be used in methods for treating atherosclerosis and preventing or reducing risk for atherosclerotic disease events. The compounds are also useful for... Agent:

20110207749 - Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase: The present disclosure is generally directed to compounds that can inhibit DAGLα and/or β activity, compositions comprising such compounds, and methods for inhibiting DAGLα and/or β activity.... Agent: Bristol-myers Squibb Company

20110207748 - Tri-aryl/heteroaromatic cannabinoids and use thereof: e

20110207751 - Heterocyclic compounds and uses as anticancer agents: Novel compounds having a fused bicyclic heteroaromatic ring system substituted with a thiazole ring are disclosed. The compounds inhibit growth of a variety of types of cancer cells, and are thus useful for treating cancer. Efficacy of these compounds is demonstrated with a system for monitoring cell growth/migration, which shows... Agent:

20110207752 - P70 s6 kinase inhibitor and egfr inhibitor combination therapy: The present invention provides a combination therapy comprising the compound 4-[4-[4-(4-fluoro-3-trifluoromethyl-phenyl)-1-methyl-1H-imidazol-2-yl]-piperidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine, or a pharmaceutically acceptable salt thereof, and an EGFR inhibitor for use in the treatment of glioblastoma multiforme, adenocarcinomas of the colon, non-small-cell lung cancer, small-cell lung cancer, cisplatin-resistant small-cell lung cancer, ovarian cancer, leukemia, pancreatic cancer, prostate cancer,... Agent: Eli Lilly And Company

20110207753 - Methods for treating pain: The invention also provides methods for diagnosing pain or a peripheral nerve lesion in a mammal by measuring the levels of BH4 or its metabolites in biological sample. Alternatively, pain or a peripheral nerve lesion may be diagnosed by measuring the levels or activity of any one of the BH4... Agent: The General Hospital Corporation

20110207754 - Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors: The present invention relates to cyclobutane and methylcyclobutane derivatives, as well as their salts, compositions, and methods of use, which are Janus kinase (JAK) inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer and myeloproliferative disorders.... Agent: Incyte Corporation

20110207755 - Use of myeloperoxidase (mpo) inhibitors or pharmaceutically acceptable salts thereof to treat multiple sysyem atrophy (msa) 938: The present invention relates to the use of MPO inhibitors for the treatment of multiple system atrophy. The present invention also relates to the use of MPO inhibitors for the treatment of Huntington's disease. The present invention also relates to the use of MPO inhibitors for neuroprotection.... Agent: Astrazeneca Ab

20110207756 - Antitumor agent for thyroid cancer: e

20110207757 - Tricyclic compounds having cytostatic and/or cytoxic activity and methods of use thereof: The present invention provides tricyclic compounds having cytostatic and cytotoxic activity in a single molecule having receptor tyrosine kinase(s), dihydrofolate reductase, thymidylate synthase and/or dihydroorotate dehydrogenase inhibitory activity, which are useful as anti-angiogenic and anti-tumor agents. Also provided are methods of utilizing these inhibitors to treat tumor cells and other... Agent: Duquesne University Of The Holy Ghost

20110207758 - Methods for therapeutic renal denervation: Methods for therapeutic renal denervation are disclosed herein. One aspect of the present application, for example, is directed to methods that block, reduce and/or inhibit renal sympathetic nerve activity to achieve a reduction in central sympathetic tone. Renal sympathetic nerve activity may be altered or modulated along the afferent and/or... Agent: Medtronic Vascular, Inc.

20110207759 - Method for treatment of atherosclerotic disease: A method of effecting regression of atherosclerotic disease in a patient whose plasma lipid concentrations are at levels considered normal or optimal. The method involves treating the patient with a combination of a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor and niacin. Disease regression has been observed over periods as short as 14... Agent:

20110207760 - Sn-38 compositions: In one aspect, the present invention is directed to a stable aqueous composition including (a) SN-38; (b) a sulfoalkyl derivative of a cyclodextrin; and (c) water; in which the concentration of SN-38 in the composition is at least about 0.13 mg/g of the composition. In another aspect, this invention is... Agent:

20110207763 - 8-carboxamido-2,6-methano-3-benzazocines:

20110207761 - Diversion- and/or abuse-resistant aompositions and methods for making the same: A composition formulated for diversion- and/or abuse-resistance, includes at least one active pharmaceutical ingredient (API), each present in an acidic form, a first compound capable of coupling to the acidic form of the API to form a complex, where the resulting complex is resistant to separation by conventional separation methods,... Agent:

20110207762 - Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.... Agent: Purdue Pharma Lp

20110207764 - Cyclopolysaccharide compositions: The present invention is directed to a composition including: (a) an active ingredient other than bendamustine; (b) a charged cyclopolysaccharide comprising at least one charged group; and (c) a stabilizing agent comprising at least one charged group having a charge opposite to that of the cyclopolysaccharide. The composition provides unexpectedly... Agent:

20110207765 - Topical composition comprising a combination of at least two penetration enhancing agents: The present invention relates to a composition for improved transdermal drug delivery comprising a drug, a combination of at least two penetration enhancing agents, wherein at least one of the penetration enhancing agents is selected from the group consisting of esters of saturated or unsaturated fatty acids and lower alcohols,... Agent: Moberg Derma Ab

20110207766 - Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed... Agent: Graceway Pharmaceuticals, LLC.

20110207767 - Novel cc-1065 analogs and their conjugates: This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span... Agent:

20110207768 - Pharmaceutical combination of antibacterial and antifungal cream: A method for the emperic treatment of an intertrigal skin infection potentially caused by a gram-positive bacteria in a human patient that includes a topical administration to the patient of a pharmaceutical formulation comprising a bactericidal amount of a Gram-positive bactericide and an antimycotic amount of an antifungal component suspended... Agent: Quadrx Pharmaceuticals

20110207770 - Pharmaceutical product comprising a muscarinic receptor antagonist and a second active ingredient: The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a selected muscarinic receptor antagonist, and a second active ingredient which is selected from a phosphodiesterase inhibitor, a modulator of chemokine receptor function, an inhibitor of kinase function, a protease inhibitor, a steroidal glucocorticoid... Agent: Pulmagen Therapeutics (synergy) Limited

20110207769 - Stable crystalline salt of (r)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabicyclo [2.2.2]oct-3-yl ester: The present invention refers to a stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabicyclo[2.2.2]oct-3-yl ester and its use as medicament, in particular for the treatment of urinary incontinence or other diseases involving genitourinary disorders... Agent: Laboratorios Salvat, S.a.

20110207772 - Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase: The present disclosure is generally directed to compounds that can inhibit DAGLα and/or β activity, compositions comprising such compounds, and methods for inhibiting DAGLα and/or β activity.... Agent: Bristol-myers Squibb Company

20110207771 - N-(l-alkyl-2-phenylethyl)-carboxamide derivatives and use thereof as fungicides: Compounds of the formula (I) in which the substituents are as defined in claim 1 are suitable for use as microbiocides.... Agent: Syngenta Crop Protection, Inc.

20110207773 - Novel phenyl-quinoline-carboxylic acid pyridine derivatives useful as modulators of nicotinic acetylcholine receptors: This invention relates to novel phenyl-quinoline-carboxylic acid pyridine derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of... Agent: Neurosearch A/s

20110207774 - Triazolothiadiazole inhibitor of c-met protein kinase: The present invention relates to compound 1, which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising Compound 1 and methods of using the compositions in the treatment of proliferative disorders.... Agent: Vertex Pharmaceuticals Incorporated

20110207775 - Agent that modulates physiological condition of pests, involved in insect vesicle-fusing atpase activity: The present invention provides an agent that modulates physiological condition of pests, wherein the agent has an ability to modulate the activity of an insect vesicle-fusing ATPase; a method for assaying pesticidal activity of a test substance, which comprises measuring the activity of a vesicle-fusing ATPase in a reaction system... Agent: Sumitomo Chemical Company, Limited

20110207776 - Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists: The present invention relates to the use of compounds and compositions of compounds having D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic activity for the treatment of the underlying dysregulation of the emotional functionality of mental disorders (i.e. affect instability—hypersensitivity—hyperaesthesia—dissociative phenomena—etc). The invention also relates to methods comprising administering... Agent:

20110207777 - Benzimidazoles which have activity at m1 receptor and their uses in medicine: e

20110207778 - Active compound combination comprising azadirachtin and a substituted enaminocarbonyl compound: Disclosed are novel active compound combinations comprising at least one substituted enaminocarbonyl compound and azadirachtin, which combinations are highly suitable for controlling animal pests such as insects and unwanted acarids. Methods of controlling insects and acarids are also disclosed.... Agent: Bayer Cropscience Ag

20110207779 - Process for the preparation of esomeprazole magnesium: The present invention relates to a process for the preparation of esomeprazole magnesium containing R-isomer greater than about 0.1% by wt. In particular, the present invention relates to a process for the preparation of esomeprazole magnesium dihydrate containing R-isomer greater than about 0.1% by wt.... Agent: Glenmark Generics Ltd

20110207780 - Therapeutic salt compositions and methods: Therapeutic salt compositions and methods are disclosed herein.... Agent:

20110207782 - Nicotine-containing product: A nicotine-containing product comprising a pharmaceutically acceptable polymeric substrate, which is able to bind cations, nicotine or a pharmaceutically acceptable nicotine derivative, and pharmaceutically acceptable inorganic cations. It further pertains to a method for the preparation of such a nicotine-containing product and to the use thereof for the preparation of... Agent: Siegfried Ltd.

20110207781 - Novel microbiocides: Compounds of Formula (I), in which the substituents are as defined in claim 1, are suitable for use as microbiocides.... Agent: Syngenta Crop Protection, Inc.

20110207783 - Renin inhibitors: The present invention relates to acyclic amino amide renin inhibitor compounds and their use in treating cardiovascular events and renal insufficiency.... Agent:

20110207784 - Oxadiazole-2-oxides as antischistosomal agents: The invention provides 1,2,5-oxadiazole-containing compounds of Formula (I), wherein R1, A, and R2 are as defined herein, that are useful in treating schistosomiasis. The invention also provides a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, and a method of treating schistosomiasis in a... Agent: Illinois State University

20110207785 - 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them: The present invention relates to (R,S) 2-aryl-propionic acids and derivatives, their single enantiomer (S) and to pharmaceutical compositions containing them, which are used in the prevention and treatment of tissue damage due to the exacerbated recruitment of polymorphonucleated neutrophils (PIvTN leukocytes) at inflammation sites. The present invention provides compounds for... Agent: Dompe S.p.a.

20110207787 - Antimicrobial compositions: What is described herein are antimicrobial compositions which are defined blends of a 1,2-diol and phenoxyethanol which show broad activity against bacteria, fungi and mold spores. This activity is potentiated by the addition thereto of small amounts of a co-biocide for which the blend acts as a delivery system for... Agent: Isp Investments Inc.

20110207786 - Potentiated biocidal compositions and methods of use: The present technology relates to biocidal compositions and methods that contain and utilize at least one biocidal agent and at least one potentiator system wherein the resultant combination has an enhanced biocidal efficacy. The present technology also discloses a rapid screening assay for determining biocidal compositions with enhanced efficacy, e.g.,... Agent:

20110207788 - 5-ring heteroaromatic compounds and their use as binding partners for 5-ht5 receptors: The invention relates to 5-ring heteroaromatic compounds of general formula (I), their use for the treatment and/or prevention of diseases, and medicaments containing same.... Agent:

20110207789 - Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents: Disclosed are methods related to label-free biosensor cellular assays to classify multienzyme complex modulators in live cells. Disclosed are also methods related to the identification of purinosome disrupting Casein Kinase II (CK2) inhibitors, and methods related to the use of purinosome disrupting CK2 inhibitors as therapeutic agents for modulating CK2... Agent:

20110207791 - Composition of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto: The present invention relates to certain compositions of a 5-HT2A serotonin receptor modulator and methods for their preparation. The compositions disclosed herein are useful for increasing slow wave sleep, improving sleep consolidation, improving sleep maintenance and improving sleep quality, and for treating insomnia and related sleep disorders, dyssomnias, parasomnias and... Agent: Arena Pharmaceuticals, Inc.

20110207790 - Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto: The present invention is directed to processes and intermediates useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea (Compound I), crystalline forms and solvate forms thereof; and compositions comprising 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea, crystalline forms and solvate forms thereof prepared by processes as described herein.... Agent:

20110207792 - Polymorphs and amorphous forms of 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1h-pyrazole-3-carbonitrile: The present invention relates to novel crystalline polymorphs, solvate pseudomorphs and amorphous form of 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile (fipronil). The present invention also provides methods for preparing the novel polymorphs, pseudomorphs and amorphous form, as well as insecticidal or pesticidal compositions comprising same, and methods of use thereof as pesticidal agents.... Agent: Makhteshim Chemical Works Ltd.

20110207793 - 1-aminocyclohexane derivatives for the treatment of sleep disorders.: The present invention relates to the treatment of an individual afflicted with sleep disorders associated with tinnitus and/or neurological diseases comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.... Agent:

20110207794 - Pharmaceutical composition: e

20110207804 - Compositions for the treatment of neoplastic diseases: Solid pharmaceutical taxane compositions for oral administration which comprise a substantially amorphous taxane, a carrier, and a surfactant, wherein the substantially amorphous taxane is prepared by a solvent evaporation method, such as spray drying. Methods of preparation of the composition and uses of the composition also are included.... Agent: Stichting Het Nederlands Kanker Institut

20110207803 - Taxane pro-emulsion formulations and methods making and using the same: Taxane pro-emulsion formulations are provided. Pro-emulsion formulations are dried powders that include a taxane, oil, surfactant and sugar alcohol. Also provided are methods of making and using the pro-emulsion formulations, as well as kits that include the pro-emulsion formulations.... Agent:

20110207805 - Composition of flavanolignan and amino acid with improved water solubility: The invention relates to a composition containing flavanolignans, e.g., isolated from Silybum marianum, and basic amino acids and, optionally, other auxiliary substances, in the form of mixture, and to the method of preparation of these compositions by mixing the components and their homogenization. The invention is applicable particularly in the... Agent:

20110207806 - Formulation of dual cycloxygenase (cox) and lipoxygenase (lox) inhibitors for mammal skin care: The present invention provides a novel composition of matter comprised of a mixture of two specific classes of compounds—Free-B-Ring flavonoids and flavans—for use in the prevention and treatment of diseases and conditions associated with the skin. This composition of matter simultaneously inhibits cyclooxygenase (COX) and lipoxygenase (LOX) enzymatic activity in... Agent: Unigen, Inc.

20110207808 - Long-chain carboxychromanols and analogs for use as anti-inflammatory agents: Provided are long-chain carboxychromanol compounds useful for treating conditions associated with the need to inhibit cyclooxygenase-1, cyclooxygenase-2, and/or 5-lipoxygenase, and pharmaceutical formulations containing the compounds.... Agent: Purdue Research Foundation

20110207807 - New use for homoisoflavone or a salt thereof: The present disclosure relates to a new use of homoisoflavanone or a salt thereof. More particularly, it relates to a pharmaceutical composition for the prevention and treatment of inflammatory diseases or allergic diseases comprising homoisoflavanone represented by Chemical Formula 1 or a salt thereof, a use of homoisoflavanone or a... Agent: Catholic University Industry Academy Cooperation Foundation

20110207809 - Method of accelerating corneal wound healing: The topical ophthalmic use of 5,6,7-trihydroxyheptanoic acid and analogs for the acceleration of corneal wound healing in humans, is disclosed.... Agent: Alcon Research, Ltd.

20110207810 - N1-benzo[1,3]dioxol-5-ylmethyl-n2-substituted biguanide derivative, preparation method thereof, and pharmaceutical composition containing same: The present invention provides an N1-benzo[1,3]dioxol-5-ylmethyl-N2-substituted biguanide derivative of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing same, and a pharmaceutical composition comprising same as an active ingredient. The inventive N1-benzo[1,3]dioxol-5-ylmethyl-N2-substituted biguanide derivative exhibits improved blood glucose level- and lipid level-lowering effects even with a reduced... Agent: Korea Research Institute Of Chemical Technology

20110207811 - Use of celivarone for reducing occurrences of cardiovascular hospitalization: The invention relates to a method of reducing occurrences of cardiovascular hospitalization of a patient by administering to the patient a pharmaceutically effective dose of the compound celivarone, or a pharmaceutically acceptable salt thereof.... Agent: Sanofi-aventis

20110207812 - Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and -2,3-dihydro-1h-indenes as potassium channel modulators: e

20110207813 - Pharmaceutical composition with gelling properties containing a tyrosine derivative: The present invention relates to an injectable pharmaceutical composition with gelling properties containing:—an active principle; a hydrophobic and bio-compatible organic liquid; and an organogelling substance, the molecules of which have the capacity to bind together via bonds of low energy, wherein said organogelling substance is chosen among L-tyrosine derivatives responding... Agent: Universite De Montreal

20110207814 - Combination therapy for breast cancer treatment: The present invention provides a novel treatment which features immune therapy in the context of the functions of MSCs as a novel approach to breast cancer treatment. By identifying and elucidating the role of MSCs in the behavior of breast cancer cells at metastatic sites and also at the primary... Agent:

20110207815 - Tetrahydronaphthalene compounds: The invention relates to compounds of Formula (I) wherein R1, R2, R3, R4, R5, m and n are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers.... Agent:

20110207816 - Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules: A composition having an agent adapted to affect a multimeric protein by binding to a binding site of the multimeric protein and thereby affecting an equilibrium of units, wherein the multimeric protein has an assembly having a plurality of said units, wherein each of the units has a first complementary... Agent: Fox Chase Cancer Center

20110207817 - Anti-inflammatory compounds and compositions thereof: This invention relates to alkyl parabens, their use as anti-inflammatory agents and compositions containing them.... Agent:

20110207818 - Disinfecting and antimicrobial compositions: Broad spectrum disinfecting and microbicidal compositions of biodegradable and environmentally friendly compositions containing esters formed from fatty organic alcohols and fatty carboxylic acids. These compositions display activities against the most resistant microbial forms including bacterial spores. The preparations can be used in health care, food processing, personal care and other... Agent:

20110207819 - Fat emulsion for artificially feeding seriously ill intensive care patients: The present invention relates to a pharmaceutical preparation for the prophylaxis and treatment of critical illness polyneuropathy (CIP) and critical illness myopathy (CIM). The invention further relates to an isotonic fat emulsion comprising at least one triglyceride that comprises at least one fatty acid group having an odd number of... Agent: B. Braun Melsungen Ag

20110207821 - method of lowering circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for treatment of atherosclerosis: Embodiments of the invention comprise methods of reducing circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 and circulating Myeloperoxidase levels by administering to subjects an effective amount of a dietary oil composition containing 20-90 wt % polyunsaturated fatty acids. Lowering oxidized low density lipoprotein-beta-2-glycoprotein complex and Myeloperoxidase levels may be an effective... Agent:

20110207820 - Novel chrysochromulina species, methods and media therefor, and products derived therefrom: An algal cell that is capable of surviving in fresh water and has a high fatty acid content, an algal culture including the algal cell, methods of growing the algal culture, algal growth media, and methods for selectively adapting the algal culture are provided.... Agent: University Of Washington

20110207822 - Compositions for cleaning and disinfecting nasal tract and sinus cavity: Biodegradable compositions for cleaning and disinfecting nasal tract and sinus cavity using food additive ingredients or ingredients that are safe.... Agent:

20110207823 - 12-hour sustained-release metoclopramide: The present invention consists of an extended-release metoclopramide hydrochloride pharmaceutical composition, in 15 mg drug substance tablets, for use in gastrointestinal disorders. The formulation is mainly composed of a hydrophilic polymer, a hydrophobic polymer, a hydrophilic component and metoclopramide hydrochloride. The hydrophilic polymer is swollen by hydration when contacting water,... Agent: Posivisionary Solutions LLP

20110207824 - Formulation of an injectable paracetamol solution, method for preparing and packaging such a solution and device for packaging such a solution: A simplified paracetamol solution for an injectable and ready-to-use preparation is only composed of paracetamol, bi-distilled water and a buffer agent, the formulation having a maximal paracetamol concentration of 1 g/100 ml, a pH between 5.5 and 6.5 and an oxygen content inferior to 0.2 ppm. A method for preparing... Agent: Moly Pharma

20110207825 - Methods for concomitant administration of colchicine and macrolide antibiotics: Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.... Agent: Mutual Pharmaceutical Company, Inc.

20110207826 - Lactose and cellulose-based tableting aid: The present invention concerns a process for producing a granulate based on lactose and cellulose (derivative), a granulate obtainable by the process and its use as a tabletting excipient.... Agent: Molkerei Meggle Wasserburg Gmbh & Co. Kg

20110207827 - Method for determining sensitivity or resistance to compounds that activate the brain serotonin system: The invention relates to a method for determining whether a patient suffering from a condition that is susceptible to treatment with a compound that activates the brain serotonin system is susceptible or resistant to treatment with the compound. The method includes establishing whether the patient is a pre-adult, a transition... Agent: Cornell University

20110207828 - Methods for the prevention and treatment of cerebral ischemia: The present invention provides methods for the treatment, amelioration, or prevention of a symptom of neuronal damage associated with cerebral ischemia comprising administering compositions comprising a compound of Formula I.... Agent:

20110207829 - Control of termites, fire ants and carpenter ants: Carvone, linalool, styralyl alcohol and tetrahydrolinalool are effective for the control of termites, fire ants and carpenter ants.... Agent: Bedoukian Research, Inc

20110207830 - Composition for treating or preventing amyloid-related diseases comprising 4-o-methylhonokiol: Disclosed is a composition for treating or preventing amyloid-related diseases including 4-O-methylhonokiol as an active ingredient. More specifically, a pharmaceutical composition including 4-O-methylhonokiol, which is effective for treating or preventing amyloid-related diseases such as Alzheimer's disease, cognitive disorder, defective memory, amyloidosis, etc. is disclosed. The inventors of the present disclosure... Agent: Bioland Ltd.

20110207831 - Ready-to-use, stable emulsion: The present invention relates to a stable emulsion, ready for use, of fat-soluble vitamins or carotenoids, a process for the preparation thereof, and the use thereof as addition to animal feeds, human foods and dietary supplements, and cosmetic and pharmaceutical compositions.... Agent: Basf Se

20110207833 - Metallic pigment preparation in compacted form, method for producing the same and use thereof: A pigment preparation with metallic effect pigments in compacted form, the pigment preparation including the following components: a) 60%-95% by weight of at least one metallic effect pigment which has at least one low-refractive-index layer (low-index layer) on the metallic core of the metallic effect pigment, the low-index layer comprising... Agent:

20110207832 - Skin disinfectant composition and methods for manufacturing and using: A disinfectant active ingredient containing composition is provided. The composition includes a disinfectant active ingredient, a hydrophobic polymer/hydrophilic polymer adduct comprising a poly(vinylpyrrolidone/alkylene) copolymer wherein the alkylene group contains at least 10 carbon atoms and a poly(vinylpyrrolidone imidizole) copolymer, and at least about 50 wt. % water. The disinfectant active... Agent: Skinvisible Pharmaceuticals, Inc.

20110207834 - Highly purified polylactic acid or a derivative thereof, a salt of the same, and purification method thereof: Disclosed are a highly purified polylactic acid or a derivative thereof, or a salt thereof, and a method for purifying the same. The polylactic acid or a derivative thereof, or a salt thereof may be applied to various medical and drug carrier systems, or the like.... Agent: Samyang Corporation

20110207835 - Alpha, beta, unsaturated nitriles as fragrances: The use of short chain α,β-unsaturated nitriles as flavour and fragrance ingredient and flavour and fragrance applications comprising them.... Agent: Givaudan Sa

  
08/18/2011 > patent applications in patent subcategories. inventions list

20110201539 - Detecting succinylacetone: This invention relates, inter alia, to detecting and/or measuring succinylacetone and one or more additional biological analytes using mass spectrometry.... Agent: Perkinelmer Health Sciences, Inc.

20110201540 - Glycosylation of molecules: Described herein are methods and genetically engineered cells useful for producing an altered N-glycosylation form of a target molecule. Also described are methods and molecules with altered N-glycosylation useful for treating a variety of disorders such as metabolic disorders.... Agent:

20110201541 - Tissue occluding agent: s

20110201542 - Myeloid protein activation of anti-inflammatory and anti-hypoxic pathway: Provided are methods to enhance healing of wounds and tissue, especially during or pursuant to psychological and/or physical stress and to protect tissue from deleterious effects associated with oxidative, psychological and/or physical stress, including but not limited to extreme exertion, ischemia, infarct, and damage associated with reperfusion of ischemic or... Agent: The Board Of Trustees Of The University Of Illinois

20110201543 - Use of tight junction antagonists in the treatment of acute lung injury and acute respiratory distress: The present application provides compositions and methods for treating acute lung injury and acute respiratory distress syndrome. The methods include administering one or more tight junction antagonists to the lung of a subject in need thereof.... Agent:

20110201544 - Compositions and methods for inhibiting the interaction between cftr and cal: The present invention features compositions and methods for increasing the cell surface expression of degradation-prone CFTR proteins and preventing or treating cystic fibrosis. The invention provides peptides and peptidomimetics that selectively inhibit the interaction between CAL and mutant CFTR proteins, thereby stabilizing the CFTR and facilitating transport of the same... Agent:

20110201545 - Gel based livestock feed, method of manufacture and use: A method of making a gel-type livestock feed includes initially forming a feed mixture by mixing feed nutrient components, water, alginate, and a calcium component insoluble in water or a sequestrate to inhibit the calcium component from reacting with the alginate. Once the feed mixture is formed, the calcium component... Agent: Purina Mills, LLC

20110201546 - Methods of treatment using single doses of oritavancin: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against a wide range of bacteria. Methods for the treatment, prophylaxis and prevention of bacterial infection and disease in animals, including humans, using a single dose of oritavancin over the course of therapy, are described.... Agent: Targanta Therapeutics Corp.

20110201547 - Engineered polypeptide agents for targeted broad spectrum influenza neutralization: The present invention provides novel agents for broad spectrum influenza neutralization. The present invention provides agents for inhibiting influenza infection by bind to the influenza virus and/or hemagglutinin (HA) polypeptides and/or HA receptors, and reagents and methods relating thereto. The present invention provides a system for analyzing interactions between infolds... Agent: Massachusetts Institute Of Technology

20110201548 - Therapeutic agent for acute hepatitis or prophylactic/therapeutic agent for fulminant hepatitis: When acute hepatitis progresses to fulminant hepatitis, a large amount of hepatic cells are rapidly broken, and as a result, the prognosis is seriously worsened. Thus, it is important to prognose the progress of acute hepatitis into fulminant hepatitis at an early stage and quickly start an appropriate treatment therefor.... Agent: Nihon Pharmaceutical Co., Ltd.

20110201549 - Enhancement of bacillus thuringiensis cry toxicities to lesser mealworm alphitobius diaperinus: The subject invention relates in part to the discovery that BtBooster (BtB) peptides enhance Bt strain and Cry protein toxicity to the lesser mealworm. The subject invention also relates in part to the discovery that Bt tenebrionis producing Cry3Aa crystals and Bt japonensis BuiBui producing Cry8Ca crystals are insecticidal to... Agent: The University Of Georgia Research Foundation, Inc

20110201550 - Combination of amidine derivatives with cyclic depsipeptides: The present invention relates to the combination of aminophenylamidine derivatives with cyclic depsipeptides, to products comprising this combination, and to the use of these active substances in combination for controlling endoparasites in humans and in animals.... Agent: Bayer Animal Health Gmbh

20110201551 - Peptide having anti-diabetic activity and use thereof: The present invention provides a composition (a blood glucose increase inhibitor) that has an effect of lowering blood glucose level in a hyperglycemic patient and that is therefore used to reduce blood glucose level in the patient. The present invention further provides a composition that is used to prevent or... Agent: Mg Pharma Inc.

20110201552 - Isolated nucleic acid molecule encoding a neurotrophic growth factor: There is disclosed an isolated nucleic acid molecule encoding a human neurotrophic growth factor designated enovin and having the amino acid sequence illustrated in FIG. 1, 21, 23 or 24 or encoding a functional equivalent, derivative or bioprecursor of said growth factor. The growth factor preferably comprises the amino acid... Agent: Janssen Pharmaceutica N.v.

20110201553 - Systemic pro-hemostatic effect of sympathicomimetics with agonistic effects on alfa-adrenergic and/or beta-adrenergic receptors of the sympathetic nervous system, related to improved clot strength: The present invention relates to a novel use and methods of treatment using sympathicomimetic agonists with pro-hemostatic activity.... Agent: Hemostatis Holding Aps

20110201554 - Hfsh aqueous formulation: Provided is an aqueous formulation of a human follicle stimulating hormone (hFSH) which is stabilized to maintain the activity of hFSH for a prolonged period of time. The formulation of the present invention is an aqueous formulation comprising a therapeutically effective amount of hFSH stabilized in a phosphate buffer containing... Agent: Lg Life Sciences, Ltd.

20110201555 - Novel estrogen receptor ligands: o

20110201556 - Methods of treating cartilage defects: The present invention provides methods of repairing and regenerating cartilage tissue by administering into the cartilage or the area surrounding the cartilage a composition comprising a therapeutically effective amount of a morphogenic protein.... Agent:

20110201558 - Anaplerotic therapy for alzheimer's disease and the aging brain: The present invention describes methods and compositions for the treatment of neurodegenerative conditions including Alzheimer's disease (AD) and aging. The present invention discloses an anaplerotic diet therapy for the treatment of AD. The high fat, low carbohydrate diet described in the various embodiments of the present invention increasing circulating ketone... Agent: Baylor Research Institute

20110201557 - Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory: The disclosure relates generally to neurodegenerative disorders and more specifically to a group of presenilin/G-protein/c-src binding polypeptides and methods of use for modulating signaling and progression of Alzheimer's disease.... Agent: The Regents Of The University Of California

20110201559 - New optically pure compounds for improved therapeutic efficiency: The present invention relates to new optically pure compounds displaying an improved anticancer activity compared to previously known complex mixtures of stereoisomers thereof. Such compounds are of formula (I): wherein each X independently represents any amino acid; n is 0 or 1; m is an integer between 0 and 3;... Agent: Immupharma (france)

20110201560 - Peptides for inhibiting the hpv-e6 oncoprotein: The present invention is concerned with means and methods for diagnosing or treating HPV associated neoplasia or tumors. Specifically, it relates to a peptide comprising an amino acid sequence motif as shown in SEQ ID No: 1. Moreover, contemplated by the present invention are fusion polypeptides, polynucleotides, vectors and host... Agent: Dkfz Deutsches Krebsforschungszentrum, Stiftung Des Offentlichen Rechts

20110201561 - Treatment of metastatic colon cancer with b-subunit of shiga toxin: The present invention relates to compositions and methods for treating invasive or metastatic cancer, particularly metastatic colon cancer using the B-submit of shiga toxin. The invention further provides methods of identifying compounds usefully for the treatment of invasive or metastatic cancer, particularly metastatic colon cancer.... Agent: The Johns Hopkins University

20110201562 - Formulations and method for treating baldness: The present invention includes 1) a novel formulation for the treatment of hair loss comprising oleanolic acid (a 5α-reductase inhibitor), apigenin (a vasodilator), and biotinyl-GHK (a cell metabolism stimulant), 2) a novel additive for the treatment of hair loss comprising oleanolic acid, apigenin, biotinyl-GHK and a delivery agent, 3) a... Agent: Sederma

20110201563 - Chimeric small molecules for the recruitment of antibodies to cancer cells: The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through... Agent: Yale University

20110201564 - Substituted 7-sulfanylmethyl, 7-sulfinylmethyl and 7-sulfonylmethyl indoles and use thereof: The present application relates to novel 7-sulfanylmethyl-, 7-sulfinylmethyl- and 7-sulfonylmethylindole derivatives, processes for the preparation thereof, the use thereof alone or in combinations for the treatment and/or prevention of diseases, and the use thereof for the manufacture of medicaments for the treatment and/or prevention of diseases, especially for the treatment... Agent: Bayer Schering Pharma Aktiengesellschaft

20110201565 - Luteolin and diosmin/diosmetin as novel stat3 inhibitors for treating autism: The present invention includes methods for the treatment of autoimmune disorders such as autism, schizophrenia, and type 1 diabetes. Flavonoids, luteolin, diosmin, and diosmin's aglycone form, diosmetin, were found to inhibit activation/phosphorylation of STAT3 induced by IL-6 in cultured neuronal cells. Furthermore, mice treated with diosmin showed a significant reduction... Agent: University Of South Florida

20110201566 - Methods for treating resistant diseases using triazole containing macrolides: Triazole-containing macrolide and ketolide antibiotics, therapeutic compositions containing them and methods of use for treating diseases caused by one or more resistant organisms are described.... Agent: Cempra Pharmaceuticals, Inc.

20110201567 - Ivermectin antagonizes ethanol inhibition in p2x4 receptors: A method for reducing alcohol consumption in a subject includes a step of identifying a subject exhibiting at least one symptom of alcoholism and then administering a therapeutically effective amount of an Ivermectin analogue-containing composition to the subject. A method of screening Ivermectin analogues for reducing alcohol consumption is also... Agent: University Of Southern California

20110201568 - Phyotochemical composition and a process thereof: The present invention is successful in providing caffeic acid derivatives namely eicosanyl caffeate and docosyl caffeate from Glycyrrhiza. Also, the present invention provides a composition comprising said bio actives and also provides a process to prepare the composition. Ultimately, the invention provides solution for the management of ulcer.... Agent:

20110201671 - Compositions and methods for inhibiting expression of a gene from the ebola virus: The invention relates to a double-stranded ribonucleic acid (dsRNA) FOR INHIBITING THE expression of a gene from the Ebola virus.... Agent: Alnylam Pharmaceuticals, Inc.

20110201667 - Compositions and methods for silencing ebola virus gene expression: The present invention provides compositions comprising therapeutic nucleic acids (e.g., interfering RNA such as siRNA) that target Ebola virus (EBOV) gene expression and methods of using such compositions to silence EBOV gene expression. More particularly, the invention provides unmodified and chemically modified interfering RNA which silence EBOV gene expression and... Agent: United States Army Medical Research And Materiel Command

20110201669 - Methods and compositions for the diagnosis and treatment of cancer: The present invention relates to the diagnosis and treatment of cancer, and in particular breast cancer. Specifically, in some embodiments the invention relates to methods of diagnosing cancer, and in particular breast cancer, using an antibody specific for a gene product that localizes selectively to the endoplasmic reticulum of the... Agent: The Research Foundation Of State University Of New York

20110201670 - Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases: The invention relates to a double-stranded compound, preferably an oligoribonucleotide (siRNA), which down-regulates the expression of a human TGaseII gene at the post-transcriptional level. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The... Agent: Quark Pharmaceuticals, Inc.

20110201668 - Regulation of neurotransmitter release through anion channels: A novel use of anion channels, preferably Ca2+-activated anion channels (CAACs), in regulating release of neurotransmitters from neurons and/or astrocytes is provided. More specifically, CAAC activity regulators, agents for regulating neurotransmitter release comprising such CAAC activity regulators, and methods of screening agents for regulating neurotransmitter release using CAAC as a... Agent: Korea Institute Of Science And Technology

20110201673 - Lpl variant therapeutics: The invention provides for the use of a therapeutic derived from a truncated lipoprotein lipase protein (LPL S447X), including nucleic acids encoding such proteins, for the treatment of conditions including LPL responsive conditions, such as cardiovascular disease, hypertension, LPL deficiency, high triglyceride levels, low HDL-cholesterol levels or atherosclerosis.... Agent:

20110201676 - Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides: The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.... Agent: The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Service

20110201675 - On01910.na enhances chemotherapeutic agent activity in drug-resistant tumors: The invention includes compositions and methods of treatment of cancers susceptible to treatment with nucleotide analog chemotherapeutic agent, including cancers in which nucleotide analog resistant tumors have developed, including identifying a subject having cancer susceptible to treatment with a nucleotide analog chemotherapeutic agent and a mitotic disruptor/polo-like kinase (Plk) pathway... Agent: The Johns Hopkins University

20110201677 - Promoters exhibiting endothelial cell specificity and methods of using same: An isolated polynucleotide functional as a promoter in eukaryotic cells is disclosed. The isolated polynucleotide includes an endothelial specific enhancer element as detailed herein. Further disclosed is a method of expressing a nucleic acid sequence of interest in endothelial cells.... Agent: Vascular Biogenics Ltd.

20110201674 - Saporin-l1 inhibitors and uses thereof: Inhibitors of saporin-L1 are disclosed, as are related compositions and uses thereof, in particular in cancer therapy that employs saporin-L1-linked immunotoxins.... Agent:

20110201672 - Semi-soft c-class immunostimulatory oligonucleotides: The invention relates to specific C-Class semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. In particular the oligonucleotides are useful for treating allergy, such as allergic rhinitis and asthma, cancer and infectious disease, such as hepatitis B and hepatitis C.... Agent:

20110201569 - Methods for treating myocardial disorders: e

20110201571 - Heat sterilised injectable composition of hyaluronic acid or one of the salts thereof, polyols and lidocaine: An injectable aqueous composition of hyaluronic acid or one of the salts thereof, one or more polyol(s) and lidocaine is used for cosmetic purposes or for therapeutic purposes. It has improved viscoelastic rheological properties and long in vivo persistence. The polyol is chosen, for example, from glycerol, sorbitol, propylene glycol,... Agent: Anteis S.a.

20110201570 - Nucleus pulposus filler: The present invention provides a nucleus pulposus filler or the like which is to be packed into an area in deformed intervertebral disc wherein normal nucleus should be located and can be stabley maintained for a long time More preferably, the present invention provides a nucleus pulposus filler comprising a... Agent: Seikagaku Corporation

20110201573 - Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them: The present invention relates to mixtures of polysaccharides derived from heparin having a mean molecular weight of 1500 to 3000 Daltons and an anti-Xa/anti-IIa ratio greater than 30, their method of preparation and pharmaceutical compositions containing them.... Agent: Aventis Pharma S.a.

20110201572 - Pharmaceutical composition with glycosaminoglycans and use thereof in the treatment of chronic ulcers: The invention relates to a composition of glycosaminoglycans for the treatment of diabetic foot ulcer, it specifically relates to low molecular weight heparins (LMWHs) and very low molecular weight heparins (VLMWHs) in the treatment of chronic ulcers, particularly of diabetic foot ulcers, and more specifically in the manufacture of a... Agent: Laboratorios Farmaceuticos Rovi, S.a.

20110201574 - Fatty acid amide hydrolase inhibitors: The present invention provides fatty acid amide hydrolase inhibitors, solid forms thereof, compositions thereof, and methods of making and using the same.... Agent:

20110201575 - Stabilized solid dispersion of adefovir dipivoxil and preparation method thereof: The present invention relates to an amorphous solid dispersion with improved stability comprising 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine as a nucleotide analogue, a pharmaceutical composition comprising the same, and a method for preparing the same.... Agent: Cj Cheiljedang Corporation

20110201577 - Processes and intermediates for the preparation of oseltamivir and analogs thereof: The present application relates to processes for the preparation of oseltamivir and the H3PO4 salt of oseltamivir, Tamiflu®. The application further relates to novel intermediate compounds and to pharmaceutical compositions containing said compounds. The application further relates to a method of using the novel intermediates to treat or prevent influenza.... Agent: Brock University

20110201576 - Small molecule inhibitors of stat3 with anti-tumor activity: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The... Agent: University Of Central Florida

20110201578 - Composition and methods for the treatment of pseudofolliculitis barbae and skin irritation: The invention comprises a composition for the treatment of pseudofolliculitis barbae and a method of use therefor. Preferred embodiments include compositions containing one or more of active ingredients L-arginine, acetylsalicyclic acid, and salicyclic acid adjusted to a pH in the range of 4.0 to 6.0. Preferred compositions include: a carrier,... Agent:

20110201579 - Method of improving the overall health of a patient by application of pregnenolone: A method is described herein for improving the overall health of a patient by providing subcutaneous pellets containing pregnenolone to at least one part of the body of the patient. In another embodiment, pregnenolone is mixed with DHEA into a cream and the resulting pregnenolone/DHEA cream is applied to at... Agent:

20110201583 - Guanidine-containing compounds useful as muscarinic receptor antagonists: or a pharmaceutically acceptable salt thereof, wherein R1-3, R5-7, a, X, Y, Y′, Y″, and Z are as defined in the specification. These compounds are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of using such compounds to, for... Agent: Theravance, Inc.

20110201582 - Method and composition for treatment of skin conditions: A method for treating dermatological conditions as eczema, seborrheic dermatitis, psoriasis and allergic skin reactions such as hives, skin irritations, poison ivy, poison oak, and the like. The method involves applying to the affected area of the skin a few drops of a combination of pheniramine maleate and either naphazoline... Agent:

20110201581 - Novel compounds 010: m

20110201580 - Pyrrolidine derivatives: The present invention relates to novel anti-inflammatory and antiallergic compounds of the glucocorticosteroid series, methods of preparing such compounds, pharmaceutical compositions comprising them, combinations and therapeutic uses thereof. More particularly, the invention relates to glucocorticosteroids that are derivatives of pyrrolidine.... Agent: Chiesi Farmaceutici S.p.a.

20110201584 - Certain chemical entities, compositions, and methods: Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.... Agent:

20110201586 - Pharmaceutical composition and method for treating hypogonadism: A pharmaceutical composition useful for treating hypogonadism is disclosed. The composition comprises an androgenic or anabolic steroid, a C1-C4 alcohol, a penetration enhancer such as isopropyl myristate, and water. Also disclosed is a method for treating hypogonadism utilizing the composition.... Agent:

20110201585 - The use of oestrogen applied to the penis to reduce hiv infections: A method of reducing or inhibiting the risk of infection from sexually transmitted viral infections (STIs), such as HIV and HPV, comprising the topical administration of oestrogenic compounds, analogues or metabolites thereof or oestrogen agonists to a human penis. A method to increase keratinisation of the penile epithelium is also... Agent:

20110201587 - Hsp90 inhibitors and methods of use: The present invention provides methods for treating various clinical conditions associated with biological activity of HSP90 in a subject. Such methods include administering to the subject in need of such a treatment a therapeutically effective amount of a composition comprising an HSP90 inhibitor.... Agent: Bio Holding, Inc.

20110201588 - Post foaming gel composition comprising an anti-irritation agent: A personal care composition which is preferably a post-foaming gel, said composition comprising an anti-irritation agent; a water dispersible surface active agent, of a carrier comprising water; and optionally a lubricant.... Agent:

20110201592 - Therapeutic oxy-phenyl-aryl compounds and their use: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain oxy phenyl aryl compounds (referred to herein as OPA compounds), as described herein, which, inter alia, inhibit Checkpoint Kinase 2 (CHK2) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds,... Agent: Cancer Research Technology Limited

20110201593 - Tricyclic heterocyclic compounds, compositions and methods of use thereof: e

20110201591 - Isonicotinamide orexin receptor antagonists: The present invention is directed to isonicotinamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use... Agent:

20110201589 - New bradykinin b1 antagonists: The invention relates to compounds of formula (I) wherein R1, R1a, R1b, R2, R3 and X, X1, X2, X3 have the meaning as cited in the description and the claims. Said compounds are useful as Bradykinin B1 antagonists. The invention also relates to pharmaceutical compositions, the preparation of such compounds... Agent: Evotec Ag

20110201590 - Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof: The invention relates to substituted aminoindanes and analogs thereof of formula (I) and the pharmaceutical use thereof. Medicaments which comprise compounds of this type are suitable for the prevention or treatment of diverse disorders such as, for example, of respiratory disorders, cystic fibrosis disorders, acute or chronic renal disorders or... Agent: Sanofi-aventis

20110201595 - Oxazolidinyl antibiotics: e

20110201594 - Pyrido [2,3-d] pyrimidines and their use as kinase inhibitors: The present invention provides derivatives of pyrido[2,3-d]pyrimidin-7-one. These compounds are kinase inhibitors, including compounds that show anti-proliferative activity, including against tumor cells, and are useful in the treatment of diseases including cancer.... Agent:

20110201596 - Methods for providing oxidatively stable ophthalmic compositions: This invention relates to a process for improving the stability of an ophthalmically compatible solution comprising at least one oxidatively unstable ophthalmic compound.... Agent:

20110201597 - Method and composition for treating alzheimer-type dementia: There is described a method for increasing the maximal tolerated dose and thus the efficacy of an acetylcholinesterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia by decreasing concomitant adverse effects by administration of said AChEI in combination with a non-anticholinergic antiemetic agent, whereby an enhanced acetylcholinesterase... Agent:

20110201598 - Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer: A class of compounds useful in pharmaceutical compositions and methods for treating or preventing cancer is described. The compounds' ability to inhibit RET kinase is quantified, i.e., their respective RET IC50 and EC50 values are described. One such compound, known as cyclobenzaprine and herein as SW-01, has been identified as... Agent:

20110201599 - Cdk modulators: A compound according to Formula I: or a pharmaceutically-acceptable salt thereof, wherein R1, R3, A, B and D are as defined in the specification; pharmaceutical compositions thereof, and methods of use thereof.... Agent: Exelixis, Inc.

20110201600 - Chalcone linked pyrrolo[2,1-c][1, 4]benzodiazepine hybrids as potential anticancer agents and process for the preparation thereof: The present invention relates to chalcone linked pyrrolo[2,1-c][1,4]benzodiazepine hybrids and a process for the preparation there of. More particularly it relates to 7-Methoxy-8-{n[4-1-(2 or 4-substituted phenyl)-3-(4-hydroxy-3-methoxyphenyl)-2-propen-1-one]alkyl}-oxy}-(11aS)-1,2,3,11a-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one and 7-Methoxy-8-{n[-3-(4-hydroxy-3-methoxyphenyl)-1-(2,4-alkyl-3-quinolyl)-2-propen-1-one]alkyl}-oxy-(11aS)-1,2,3,11a-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one with aliphatic chain length variations useful as anticancer (antitumour) agent. The general structural formula of these chalcone linked pyrrolo[2,1-c][1,4]benzodiazepines hybrids is given... Agent:

20110201601 - Inhibitors of the shiga toxins trafficking through the retrograde pathway: The present invention relates to the use of compounds of general formula (I) and (II) for the preparation of a drug for preventing and/or treating disorders caused by Shiga toxins and related toxins.... Agent: Centre Nat De La Recherche Scientifique

20110201603 - Novel acylaminobenzamide derivatives: The present invention relates to novel Acylaminobenzamide derivatives represented by the following formula (I) and use thereof as pesticides: wherein V represents an aromatic ring group of V1 to V5 described in the detailed description, Q represents an aromatic ring group of Q1 to Q7 described in the detailed description,... Agent: Bayer Cropscience Ag

20110201602 - Protein kinase modulators and method of use: wherein A, B, D, E, G, H1-5 and R1-4 are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of these kinases. For example, the compounds are capable of modulating kinase enzymes... Agent: Amgen Inc.

20110201604 - Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof: Substituted fused imidazole derivatives, methods of their preparation, pharmaceutical compositions comprising a substituted fused imidazole derivative, and methods of use in treating inflammation are provided. The substituted fused imidazole derivatives may control the activity or the amount or both the activity and the amount of heme-oxygenase.... Agent: High Point Pharmaceuticals, LLC

20110201607 - Fused heterocyclic m1 receptor positive allosteric modulators: The present invention is directed to fused heterocyclic compounds of formula (I): which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to... Agent:

20110201605 - Heteroaryl substituted piperidines: or to pharmaceutically active acid addition salts thereof. The compounds of formula I are modulators for amyloid beta and thus may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral... Agent:

20110201606 - Pyrimidine derivatives:

20110201608 - Substituted naphthyridines and use thereof as medicines:

20110201610 - Aryl sulfonamides: The present invention relates to compounds that modulate various chemokine receptors. These compounds are useful for treating inflammatory and immune diseases.... Agent:

20110201612 - Compositions for modulating a kinase cascade and methods of use thereof: The invention relates to compositions comprising 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts. The invention provides an efficient process for the synthesis of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts and methods for modulating one or more components of a kinase cascade using the compositions of the invention. The present... Agent: Kinex Pharmaceuticals, LLC

20110201611 - Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof: The invention relates to compositions comprising 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts. More specifically, the invention provides an efficient process for the synthesis of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts and methods for modulating one or more components of a kinase cascade using the compositions of the invention.... Agent: Kinex Pharmaceuticals, LLC

20110201609 - Proteasome inhibitors for selectively inducing apoptosis in cancer cells: e

20110201613 - Fungicide hydroximoyl-tetrazole derivatives:

20110201614 - Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals: Embodiments of this invention provide methods for therapeutic use of cyclic G-2-Allyl Proline to treat cognitive disorders as well as manufacture of medicaments including tablets, capsules, injectable solutions that are useful for treatment of such conditions.... Agent:

20110201615 - Triazole beta carboline derivatives as anti-diabetic agents: Beta-carboline derivatives of structural formula (I) are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also... Agent:

20110201616 - Sulfonamide compounds or salts thereof: [Means for Solution] The present inventors investigated EP1 receptor antagonists, and confirmed that a compound having a sulfonamide structure, in which the nitrogen atom of the sulfonamide structure is substituted with 2-fluoropropyl group, 3-fluoro-2-methylpropyl group or the like, has a potent EP1 receptor antagonistic action, thereby completing the present invention.... Agent: Astellas Pharma Inc.

20110201617 - Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity: New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.... Agent: Takeda Pharmaceuticals North America, Inc.

20110201618 - Kmups inhibiting proliferation and obliteration of pulmonary artery: w

20110201619 - Use of n-phenyl-2-pyrimidineamine derivatives against mast cell-based diseases like allergic disorders: in which the symbols and substituents have the meaning as given herein in free form or in pharmaceutically acceptable salt form in the manufacture of a pharmaceutical composition for the treatment of allergic rhinitis, allergic dermatitis, drug allergy or food allergy, angioedema, urticaria, sudden infant death syndrome, bronchopulmonary aspergillosis, multiple... Agent:

20110201620 - 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors: The present invention relates to the use of masitinib or a pharmaceutically acceptable salt thereof, and in particular of masitinib mesylate, for the preparation of a medicament for the treatment of GIST, to the use of this therapy for the treatment of GIST, and a method of treating mammals, including... Agent: Ab Science

20110201621 - Angiotensin ii receptor antagonists: e

20110201623 - Crystalline form of a cyclopropyl benzamide derivative:

20110201624 - Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-iv, and other antidiabetic or antiobesity agents as active ingredients: The present invention relates to a pharmaceutical composition for the prevention and treatment of diabetes or obesity comprising as active ingredients a compound which inhibits the activity of dipeptidyl peptidase-IV (DPP-IV), a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, and one or more other antidiabetic or... Agent: Dong-a Pharmaceutical. Co., Ltd

20110201622 - Solid forms comprising a cyclopropyl amide derivative: This disclosure relates to at least one solid form of 4-{(1S, 2S)-2-[((R)-4-cyclobutyl-2-methylpiperazin-1-yl)carbonyl]-cyclopropyl}-benzamide. This disclosure also relates to at least one pharmaceutical composition comprising at least one solid form described herein, methods of using the solid forms and pharmaceutical compositions comprised thereof, and processes of manufacturing the solid forms.... Agent:

20110201625 - Organic comopunds: or a hydrate or solvate thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for... Agent:

20110201626 - 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase: The present invention relates to new 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Auspex Pharmaceuticals, Inc.

20110201627 - Freeze-dried reparation of tetrodotoxin and the producing method thereof: A stable freeze-dried powder preparation of tetrodotoxin and the producing method thereof. The freeze-dried powder preparation has tetrodotoxin as the main active ingredient, and comprises solubilizer, excipient and stabilizer. The said solubilizer is citric acid. The excipient is sodium chloride, mannitol or their composite. The stabilizer is dextran, trehalose or... Agent:

20110201628 - Heterocyclic jak kinase inhibitors: The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer.... Agent:

20110201629 - Cyclohexyl amide derivatives as crf receptor antagonists: e

20110201630 - Fused pyridine derivatives as kinase inhibitors: A series of heteroaryl-substituted fused pyridine derivatives, in particular heteroaryl-substituted thieno[3,2-6]pyridine derivatives, being selective inhibitors of PO kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.... Agent: Ucb Pharma S.a.

20110201631 - Pharmaceutical formulations comprising pemetrexed: Pharmaceutical formulations comprising amorphous pemetrexed or its salts, and processes to prepare the formulations.... Agent: Dr. Reddy's Laboratories, Inc.

20110201632 - 2,5-disubstituted piperidine orexin rceptor antagonists: The present invention is directed to 2,5-disubstituted piperidine amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and... Agent:

20110201633 - Alfuzosin tablets and synthesis: A monolithic composition includes alfuzosin in a polymeric matrix adapted to release 13-33% of the alfuzosin within 2 hours, 40-60% of the alfuzosin within 7 hours, and greater than 80% of the alfuzosin within 20 hours of administration. A unit dosage form includes: a heterogeneous mixture of alfuzosin hydrochloride, lactose... Agent: Acino Pharma Ag

20110201634 - Dihydropyridimidinone compounds for the treatment of cardiovascular diseases and process for preparing the same: The present invention relates to a dihydropyrimidinone compound of formula (I) wherein X represents O, S, etc. and R′ represents alkyl, alkoxy, thioalkyl, thioalkyloxy, phenyl, substituted phenyl, phenyloxy, substituted phenyloxy, amino, monosubstitutedamino, disubstitutedamino, aryl, heteroaryl, aryloxy, heteroaryloxy, halo; R″ represents alkoxy, phenyloxy, substituted phenyloxy, aryloxy, heteroaryloxy, halo, NR1R2 and Rn... Agent: Vallabhbhai Patel Chest Institute

20110201635 - Substituted spiroindolinones: e

20110201638 - Phenanthroindolizidine compound and nfkb inhibitor containing same as active ingredient:

20110201637 - Phenanthroindolizidine derivative and nfkb inhibitor containing same as active ingredient:

20110201636 - Use of 14,15-dihydro-20,21-dinoreburnamenin-14-ol for the treatment and/or prevention of serious depression and sleep/waking cycle disorders: The invention relates to a novel therapeutic use of 14,15-dihydro-20,21-dinoreburnamenin-14-ol for the treatment of serious depression in humans, particularly for the treatment of a patients resistant to conventional anti-depressant treatments and for treatment of sleep/waking cycle disorders.... Agent: Biocortech

20110201639 - Stabilized tacrolimus composition: The invention relates to a stable pharmaceutical composition comprising comprising a solid dispersion of tacrolimus in a vehicle further comprising a stabilizing agent capable of providing a pH below 7 in the composition, as measured after re-dispersion in water, and preventing or reducing the formation upon storage of major degradation... Agent: Lifecycle Pharma A/s

20110201640 - Tricyclic compound: Provided is a tricyclic compound having a PPAR γ agonist activity, which is represented by the general formula (I) wherein Z represents a single bond or the like, Y represents a hydrogen atom, lower alkyl optionally having substituent(s) or the like, X represents a hydrogen atom or the like, A... Agent: Kyowa Hakko Kirin Co., Ltd.

20110201641 - Indole derivatives as crth2 receptor antagonists: The compound (+) {7R-[[(4-fluorophenyl)sulfonyl] (methyl)ammo]-6,7,8,9-tetrahydropyrido[1,2-a]mdol-10-yl}acetic acid and pharmaceutically acceptable salts thereof are antagonists of the PGD2 receptor, CRTH2, and as such are useful in the treatment and/or prevention of CRTH2-meidated diseases such as asthma.... Agent: Merck Frosst Canada Ltd

20110201642 - Bioactive compounds: The invention relates to bioactive compounds derived from an endophytic Aspergillus sp. fungus strain isolated from a Malaysian medicinal plant Garcinia scortechinii and to compositions which contain one or more of these compounds. In particular, the invention relates to compounds according to formula I; or a pharmaceutically acceptable salt, solvate,... Agent:

20110201643 - Novel n-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds: Compounds of a certain formula (I) wherein R1, R2, R3, X, Y, r, s, t, u and v have the meanings as defined in the specification, and the salts, solvates and hydrates thereof are novel effective HDAC 6 inhibitors.... Agent: 4sc Ag

20110201644 - Crystalline form of a benzimidazole-carboxamide medicinal compound: The invention provides crystalline forms of the novel benzimidazole-carboxamide 5-HT4 receptor agonist compound, 4-(4-{[(2-isopropyl-1H-benzoimidazole-4-carbonyl)amino]methyl}-piperidin-1-ylmethyl)piperidine-1-carboxylic acid methyl ester. The invention also provides pharmaceutical compositions comprising the crystalline compound, methods of using the compound to treat diseases associated with 5-HT4 receptor activity, and processes useful for preparing crystalline forms of the compound.... Agent: Theravance, Inc.

20110201645 - Method of treating attention deficit disorders with d-threo methylphenidate: Methods for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS while minimizing drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential by administration of d-threo-methylphenidate or pharmaceutically acceptable salts thereof.... Agent:

20110201646 - Optical isomers of an iloperidone metabolite: The present invention relates to novel isomers of a metabolite of Iloperidone, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.... Agent:

20110201647 - [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase: useful as an inhibitor of tryptase. In addition, the present invention is directed to the use of the compound for treating a patient suffering from, or subject to, a physiological condition in need of amelioration by inhibition of tryptase, comprising administering to the patient of a therapeutically effective amount of... Agent:

20110201648 - Poly-heteroaryl derivatives for the treatment of cancer: The present invention relates to Penta-hexa-, hepta-, octa-, nona- and, deca-heteroaryl derivatives, comprising a combination of heterocycle 1 (Het-1)a and/or heterocycle 2 (Het-2)b and/or heterocycle 3 (Het-3)c and/or heterocycle 4 (Het-4)d of formulae I, II, III and IV respectively, the N-oxides, the pharmaceutically acceptable addition salts. The compounds claimed are... Agent: Museum National D'histoire Naturelle (mnhn)

20110201649 - agricultural composition: [wherein, G represents a di-valent aromatic hetero 5-membered ring optionally having a halogen atom or C1 to 3 alkyl group (with the proviso that a hetero atom of the aromatic hetero 5-membered ring is a nitrogen atom, oxygen atom or sulfur atom), R1 represents a hydrogen atom or amino group,... Agent: Sumitomo Chemical Company, Limited

20110201650 - Cyclohexane derivative and pharmaceutical use thereof: A compound has a strong analgesic action against both nociceptive pain and neuropathic pain and has less side effects, and is medically useful. The compound includes cyclohexane derivatives represented by the following compound, or pharmaceutically acceptable salts thereof or prodrugs thereof.... Agent: Toray Industries, Inc.

20110201651 - Mitotic kinesin inhibitors and methods of use thereof: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders.... Agent:

20110201652 - 2,4-disubstituted pyrrolidine orexin receptor antagonists: The present invention is directed to 2,4-disubstituted pyrrolidine amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and... Agent:

20110201653 - Method for inhibiting and/or preventing formation of cancer metastases and secondary malignant cancer: e

20110201654 - Therapeutic combination: This invention relates to pharmaceutical combinations of amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects... Agent:

20110201655 - Pharmaceutical composition improving intestinal absorption: An object of the present invention is to provide a pharmaceutical composition that improves intestinal absorption of a compound having a structure represented by the general formula [1]. The composition containing a compound represented by the general formula [1] or a salt thereof and (b) a lipophilic substance improves intestinal... Agent: Santen Pharmaceutical Co., Ltd.

20110201657 - Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly (ADP-ribose) polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes,... Agent: Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa

20110201656 - Novel diphenyl 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors: This invention relates to novel diphenyl 1,2,3-triazole derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the... Agent: Neurosearch A/s

20110201659 - Agent for preventing or treating zoster-associated pain: The present invention relates to a pharmaceutical composition and method for preventing or treating a zoster-associated pain. The inventors found that an N-{2-[(4-substituted phenyl)amino]-2-oxoethyl}tetrahydro-2H-thiopyran-4-carboxamide compound useful as a varicella-zoster virus (VZV) unexpectedly has the effect to prevent an irreversible nerve degeneration accompanied by herpes virus infection, and therefore is also... Agent: Astellas Pharma Inc.

20110201658 - Pharmaceutical package: The present invention relates to a pharmaceutical package including a pharmaceutical preparation containing 2-ethoxy-1-{[2′-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl or 2-cyclopropyl-1-{[2′-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl or a salt thereof, and a desiccant. According to the present invention, a pharmaceutical package having a decreased uncomfortable odor is provided.... Agent: Takeda Pharmaceutical Company Limited

20110201660 - Method for controlling plant disease: The combination of ethaboxam and transgenic plants provides enhanced plant protection in controlling plant disease. According to the present invention, an application of an effective amount of ethaboxam to transgenic plants applied to plant foliage parts; soil-applied in drench or soil incorporation; or applied to seed using seed slurry application,... Agent:

20110201661 - Spiro derivatives of parthenin as novel anticancer agents: The present invention relates to novel spiro derivatives of parthenin prepared by the dipolar cycloaddition of various dipoles viz, benzonitrile oxides, nitrones, azides, nitrile ylide diazoalkane, nitrile imide, ozone, azomethine imides, azomethine ylides etc. with exocyclic double bond of C ring (α-methylene-γ-butyrolactone). Representative compounds have been screened for their anticancer... Agent: Council Of Scientific & Industrial Research

20110201662 - Method for producing xps moulded pieces provided with insecticide: e

20110201663 - Benzo (f) isoindol-2-ylphenyl acetic acid derivatives as ep4 receptor agonists:

20110201664 - Methods and compositions for treatment of prostate intraepithelial neoplasia: Provided herein are methods of treatment of prostate intraepithelial neoplasia (PIN) by administering bexarotene. Also provided are pharmaceutical compositions and dosing regimens.... Agent:

20110201665 - Compositions, methods, and kits for treating influenza viral infections: The present invention provides compositions, methods, and kits for treating or preventing a viral infection (e.g., an infection caused by an influenza virus).... Agent: Excrx (singapore) Pte. Ltd. (f.k.a. Combinatorx (singapore) Pte. Ltd.

20110201666 - Compounds from mycelium of antrodia cinnamomea and use thereof: The present invention relates to compounds from mycelium of Antrodia cinnamomea. The present invention also relates to a composition and a method for treating or prophylaxis of hepatitis C virus (HCV) infection.... Agent: Simpson Biotech Co., Ltd.

20110201678 - Xanthenone-4-acetic acid derivatives: This invention relates to novel compounds that are xanthenone-4-acetic acid derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel xanthenone-4-acetic acid derivatives that are derivatives of AS 1404. This invention also provides compositions comprising one or more compounds of this invention and a carrier, and the... Agent:

20110201680 - formulation of silymarin with high efficacy and prolonged action and the preparation method thereof: A high-efficacy, long-acting formulation of silymarin, comprising silymarin solid dispersion, silymarin-loaded silica nanoparticles, slow-release matrix material and release enhancer, wherein the mass ratio of these components is silymarin solid dispersion:silymarin-loaded silica nanoparticles:slow-release matrix material:release enhancer=1:0.5˜1.25:0.1˜0.3:0.1˜0.3; the drug loading rate of the said silymarin-loaded silica nanoparticles is 51.95%-52.87%; the said silymarin... Agent: Jiangsu University

20110201679 - Use of tocotrienols for elevating ikbkap gene expression and treating neurodegenerative diseases or disorders: The present invention provides methods for elevating IKBKAP gene expression and the level of functional IKAP protein in cells, which are beneficial to human individual, such as an individual suffering from a neurodegenerative disease or disorder such as Familial Dysautonomia, by providing one or more tocotrienols alone or in combination... Agent:

20110201681 - Cleansing bars: A cleansing bar composition comprising a soap; and a wax having a melting point of about 50° C. to about 75° C., sunflower oil, and myristyl myristate. In one embodiment, the wax is beeswax. The combination of the wax, the sunflower oil, and myristyl myristate allows for the deposition of... Agent: Colgatepalmolive Company

20110201682 - Mixture of fatty acid esters of natural origin and its use in cosmetic preparations based on olive oil derivatives: Mixture comprising esters of saturated C16-C18 fatty acid and unsaturated C16-C18 fatty acids with 2-ethyl-hexyl alcohol, said esters being in an amount ranging from 90% to 100% by weight with respect to the total weight of the mixture. The cosmetic compositions containing such a mixture formulated in topical form have... Agent: B & T Srl

20110201683 - Oil containing one or more long-chain polyunsaturated fatty acids phospholipids derived from biomass: The present invention relates to a method to extract long-chain polyunsaturated fatty acids from sources using emulsifiers dispersed in oil as carrier and to the oils obtainable from such a method. It also relates to the use of emulsifier in oil for improving the extraction of long-chain polyunsaturated fatty acids... Agent: Nestec S.a.

20110201684 - Ep2 agonist from non-prostanoid structures designed as pge2 antagonists: A method of treating ocular hypertension, lowering intraocular pressure, pain or inflammation, comprising administering to a mammal a pharmaceutical composition of an EP2-receptor agonist represented by... Agent: Allergan, Inc.

20110201685 - Compositions: An ingestible particulate composition comprises: a) at least one compound selected from the group consisting of 2,4-dichlorobenzyl alcohol, amylmetacresol, cetylpyridinium chloride, hexitidine, hexylresorcinol, flurbiprofen, lidocaine, benzocaine, ibuprofen, paracetamol, pectin, menthol, and benzydamine; and b) one or more bioadhesive materials. Resulting particulate compositions have excellent flow characteristics, dust suppression, organoleptic properties... Agent: Reckitt Benckiser Healthcare (uk) Limited

20110201686 - Inhibitors of ass and synuclein aggregation: Provided are methods of inhibiting aggregation of amyloid-beta (Aβ) or accumulation of aggregated Aβ using certain guanylhydrazone compounds. Also provided are methods of treating or preventing an amyloid-related disease in a mammal, methods of treating a subject having Alzheimer's disease, methods of treating a subject at risk for Alzheimer's disease,... Agent:

20110201687 - Amide derivative, pest control agent containing the amide derivative, and use of the amide derivative: In the following Formula (1), A represents a carbon atom, a nitrogen atom, or the like, and K represents a non-metal atomic group necessary for forming a cyclic linking group derived from benzene or a heterocyclie. X represents a halogen atom or the like; n represents an integer of from... Agent: Mitsui Chemicals Agro, Inc.

20110201688 - N,n'-di-p-bromophenyl guanidine treatment for stroke at delayed timepoints: 1,3 di-o-tolylguanidine (DTG) was examined as anti-stroke drug with a broad therapeutic window. DTG activates sigma 1 and 2 receptors. Administration of DTG at 24 hours post-stroke to rats reduces neurodegeneration by 85%; this is the only pharmacological agent that has been used successfully at this delayed timepoint. Treatment with... Agent: University Of South Florida

20110201689 - Compositions containing quaternary ammonium compounds: Composition containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, the composition including at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at... Agent: Novagali Pharma Sa

20110201690 - Deuterium-enriched dapoxetine: The present application describes deuterium-enriched dapoxetine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Protia, LLC

20110201691 - Modulation of fibroblast activity: The invention includes a method for simultaneously decreasing the amount of TGFβ1 and increasing the amount of TGFβ3 produced by a fibroblast, the method comprising contacting the fibroblast with an agent which positively modulates β2-adrenergic receptor; a method for reducing fibroblast differentiation, the method comprising contacting the fibroblast with an... Agent: The University Of Leicester

20110201692 - Antimicrobial flush solutions: The present invention provides antimicrobial solutions that comprise at least one alcohol, at least one antimicrobial agent and at least one chelator and/or anticoagulant. Also provided are methods for rapidly reducing a microbe or a virus from surfaces including surfaces of indwelling medical devices and organic surfaces such as skin... Agent: The Board Of Regents Of The University Of Texas System

20110201693 - Hydroalcoholic antimicrobial composition with skin health benefits: The invention pertains to an alcohol based antimicrobial skincare composition. The invention also pertains to an alcohol based antimicrobial skincare composition with skin health benefits including moisturization and skin barrier maintenance effects. The invention further pertains to an alcohol based antimicrobial skincare composition that is a stable emulsion that has... Agent: Ecolab Usa Inc.

20110201694 - Compositions and methods for treatment of disorders of protein aggregation: The invention provides compositions, methods and uses comprising a scyllo-inositol compound that provide beneficial effects in the treatment of a disorder and/or disease including a disorder in protein folding and/or aggregation, and/or amyloid formation, deposition, accumulation, or persistence.... Agent:

20110201695 - Encapsulation of lipophilic or amphiphilic therapeutic agents in nano-emulsion: e

  
08/11/2011 > patent applications in patent subcategories. inventions list

20110195891 - Fermented milk or vegetable proteins comprising receptor ligand and uses thereof: The present invention relates to the use of compositions comprising receptor ligands obtainable by a process comprising fermenting a food material, comprising animal milk or vegetable proteins, with lactic acid bacteria to obtain a fermented food or feed material that comprises ligands of specific adrenoreceptors and/or serotonin receptors. The fermented... Agent: Chr-hansen A/s

20110195892 - Artifical pulmonary surfactant compositions: The peptides according to the present invention have a high surfactant activity, but no or little hemolytic activity and comprises D-amino acid and acids at a rate of approximately 5% to 40% of the structuring amino acids. The pulmonary surfactant composition of the present invention comprises a mixture of the... Agent:

20110195893 - Use of apolipoproteins to decrease inflammation: The invention features methods of using serum factors such as Apolipoprotein A2 and Apolipoprotein C3 for reducing or preventing a chronic or acute inflammatory response (e.g., an inflammatory response due to an autoimmune disease or an injury).... Agent: The General Hospital Corporation

20110195894 - Cd5 pharmaceutical compositions for the treatment of infectious and inflammatory processes of fungal origin: The present invention refers to pharmaceutical compositions comprising the soluble CD5 ectodomain and its use for the prevention and/or treatment of fungal infections and/or fungal sepsis, as well as inflammatory disorders of fungal origin.... Agent: Universitat De Barcelona

20110195895 - Fgf21 mutants and uses thereof: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.... Agent: Amgen Inc.

20110195896 - Isoform-specific insulin analogues: A method treating a mammal by administering a physiologically effective amount of an insulin analogue or a physiologically acceptable salt thereof where the insulin analogue displays more than twofold greater binding affinity to insulin receptor isoform A (IR-A) than insulin receptor isoform B (IR-B). The insulin analogue may be a... Agent: Case Western Reserve University

20110195897 - Glycosylated glp-1 peptide: Oligosaccharide chain added GLP-1 peptides are more stable in blood and more active in controlling blood-sugar levels than GLP-1 peptides without added oligosaccharides. Oligosaccharide chain added GLP-1 peptides having GLP-1 activity include at least one or at least two amino acids each substituted with an oligosaccharide chain added amino acid... Agent: Otsuka Chemical Co., Ltd.

20110195898 - Treatment of alzheimer's disease and mild cognitive impairment using gnrh-i analogs and one or more of acetylcholinesterase inhibitors and nmda receptor antagonists: Methods of treating, mitigating, slowing the progression of, or preventing Alzheimer's Disease and Mild Cognitive Impairment (MCI) include administration of gonadotropin-releasing hormone analogs in combination with acetylcholinesterase inhibitors and/or N-methyl-D-aspartate receptor antagonists.... Agent: Voyager Pharmaceutical Corporation

20110195899 - Formulations of human growth hormone comprising a non-naturally encoded amino acid: Formulations of modified human growth hormone polypeptides are provided.... Agent: Ambrx, Inc.

20110195900 - Peptidic pth receptor agonists: Novel peptidic pth receptor agonists and methods of using the same are provided.... Agent: Ferring B.v.

20110195901 - Artery- and vein-specific proteins and uses therefor: Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a... Agent: California Institute Of Technology

20110195902 - Fusion protein composed of matrix metalloproteinase-2 inhibitor peptide derived from amyloid-b precursor protein and tissue inhibitor of metalloproteinase-2: The present invention provides an agent capable of inhibiting MMP-2 specifically. Disclosed is a fusion molecule composed of a β-amyloid precursor protein molecule-derived domain having an activity of selectively inhibiting matrix metalloproteinase-2 and a tissue inhibitor of metalloproteinase capable of binding to latent matrix metalloproteinase. Also disclosed are a pharmaceutical... Agent: Oriental Yeast Co., Ltd.

20110195903 - Methods and compositions for detecting recessive familial fsgs and uses thereof: Described herein are genomic and proteomic biomarkers for the diagnosis of FSGS. Methods for diagnosing FSGS or a predisposition to develop FSGS using the described biomarkers are also provided. Further provided are methods for choosing a course of treatment or administering treatment based on a diagnosis of FSGS using the... Agent:

20110195904 - Methods of treatment using exendin peptides or glp-1 peptides: Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia,... Agent: Amylin Pharmaceuticals, Inc.

20110195905 - Apls for treating arthritis: One embodiment of a therapeutic composition comprises one or more APLs, e.g., APL A12, for treating diseases or disorders related to arthritis, including rheumatoid arthritis. Another embodiment includes a method of inducing a Th2-type cytokine secretion profile in a mammal, including administering a therapeutic amount of A12 analog peptide. Another... Agent: Argentis Pharmaceuticals, LLC

20110195906 - Osteogenic synthetic peptides, pharmaceutical compositions comprising the same, and medium containing the same: Disclosed herein is an osteogenic synthetic peptide, derived from bone morphogenetic protein-7, consisting of a sequence of 15 amino acid residues. Provided are also a pharmaceutical composition and a medium composition comprising the same. Having remarkable activity related to promoting osteoblast differentiation, the osteogenic synthetic peptide is very useful in... Agent: Industry Foundation Of Chonnam National University

20110195907 - Amino acid and peptide conjugates of amiloride and methods of use thereof: The present invention provides compositions comprising amiloride amino acid and peptide conjugates. Efficient methods are also provided for administering the amiloride conjugates of the present invention for treating cancer or a central nervous system disease or disorder or for preventing or reducing ischemia-reperfusion injury. Further, kits are provided for the... Agent: The Regents Of The University Of California Office Of Technology Transfer

20110195908 - Prosaposin as a neurotrophic factor: Prosaposin, saposin C and various peptide fragments of saposin C stimulate neurite outgrowth in vitro. In addition, prosaposin and saposin C promote increased myelination ex vivo. Prosaposin is present in large neurons of the brain, including both upper and lower motor neurons.... Agent: Myelos Corporation

20110195909 - Novel x-conotoxin peptides (-ii): An isolated, synthetic or recombinant χ-conotoxin peptide having the ability to inhibit neuronal amine transporter comprising the following sequence of amino acids: Cys Cys Gly Tyr Lys Leu Cys Xaa5 Xaa6 Cys, SEQ ID NO: 3, where Xaa5 and Xaa6 are independently absent or represent any amino acid residue except... Agent: Xenome Ltd.

20110195911 - Synthetic analogs of the juxtamembrane domain of igf1r and uses thereof: A peptide or peptidomimetic comprising the amino acid sequence RXGNGV (SEQ ID NO: 1) or the inverse thereof, or comprising at least six contiguous amino acids of the juxtamembrane domain of IGF1R (SEQ ID NO: 43) or inverse thereof, wherein the peptide or peptidomimetic comprises a total of about 50... Agent: The United States Of America,as Represented By The Secretary,department Of Health & Human Services

20110195910 - Use of tocotrienol composition for the prevention of cancer: The present invention is directed to a method of preventing cancer or preventing the recurrence of cancer after undergoing a cancer treatment by administering a composition comprising at least one of γ-tocotrienol or δ-tocotrienol, wherein the cancer is selected from the group consisting of melanoma, prostate cancer, prostate intraepithelial neoplasia,... Agent: Davos Life Science Pte. Ltd.

20110195912 - Oligomer-protease inhibitor conjugates: Provided are small molecule drugs that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the small molecule drug not attached to the water soluble oligomer.... Agent: Nektar Therapeutics

20110195913 - Anionic polysaccharides functionalized by at least two hydrophobic groups carried by an at least trivalent spacer: Anionic polysaccharide derivatives partially functionalized by at least two vicinal hydrophobic groups, the hydrophobic groups, which are identical or different, being carried by an at least trivalent radical or spacer, a method of synthesis of the functionalized polysaccharides, and pharmaceutical compositions having one of the polysaccharides and at least one... Agent: Adocia

20110195914 - Macrocyclic antiproliferation agents and methods of treatment: The instant invention describes macrocyclic compounds having antiproliferation activity, and methods of treating disorders such as cancer, tumors and cell proliferation related disorders.... Agent: University Of Florida Research Foundation

20110195915 - Method of inhibiting prostate cancer cell proliferation: The present invention relates to a method of inhibiting or reducing the proliferation of prostate cancer cells, such as androgen independent prostate cancer (AIPC) cells, the method comprising administering to the cells a PLA2 inhibitor. In one embodiment the PLA2 inhibitor is a conformationally constrained molecule derived from a peptide... Agent: Scott, Kieran, Francis

20110195916 - Cytokine protein family: The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-α at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral... Agent: Zymogenetics, Inc.

20110195918 - Method for producing pectin hydrolysis products: Methods for the production of pectin hydrolysis products, the pectin hydrolysis products produced in this manner, as well as their use are described.... Agent: N.v. Nutricia

20110195917 - Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate: The invention relates to a pharmaceutical composition according to the claim 1 comprising a glucopyranosyl-substituted benzene derivative in combination with a DPP IV inhibitor which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance... Agent: Boehringer Ingelheim International Gmbh

20110195919 - Combination therapy for acne vulgaris comprising administration of adapalene 0.3% gel and clindamycin/benzoyl peroxide gel: A novel regime or regimen for the treatment of acne related diseases and particularly acne vulgaris includes administering to a patient in need of such treatment a therapeutically effective amount of Differin gel 0.3% (adapalene) in association or combination with a combined clindamycin/benzoyl peroxide gel product such as DUAC®.... Agent:

20110195920 - Biodefenses using triazole-containing macrolides: Use of macrolide and ketolide antibiotics for the treatment of acute exposure and diseases caused by biodefense pathogens is described.... Agent: Cempra Pharmaceuticals, Inc.

20110195921 - Elimination of a contaminating non-human sialic acid by metabolic competition: The disclosure provides a method of reducing or eliminating Neu5Gc in a cell culture or in a human subject. The method includes flooding the system with the human sialic acid i\7-acetylneuraminic acid (Neu5Ac) in glycosidically-bound or free form, or its precursor N-acetylmannosamine (ManNAc) in an amount sufficient to metabolically compete... Agent:

20110196016 - Compositions and methods for inhibiting expression of ikk2 genes: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an IKK2 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the... Agent:

20110196017 - Micro-rna that promotes vascular integrity and uses thereof: The present invention relates to the identification of a microRNA, designated miR-126, that is a regulator of vascular integrity in endothelial cells. This endothelial cell-restricted microRNA mediates developmental angiogenesis in vivo, and targeted deletion of miR-126 in mice causes leaky vessels, hemorrhaging, and partial embryonic lethality, due to a loss... Agent:

20110196018 - Nuclease resistant external guide sequences for treating inflammatory and viral related respiratory diseases: External Guide Sequence (EGS) are described that target proteins required for generation and modification of the immunoglobulin and T-cell repertoire that are useful for treatment or prevention of inflammatory or related diseases. Formulations suitable for administration of an EGS for treatment of inflammatory or related disease are described. The formulations... Agent: Yale University

20110196019 - Treatment of cancer by inhibition of igfbps and clusterin: Agents that reduce the amount of IGFBP-2 and/or IGFBP-5 and that are known to be useful in the treatment of cancer result in increased expression of the protein clusterin. Since clusterin can provide protection against apoptosis, this secondary effect detracts from the efficacy of the therapeutic agent. In overcoming this,... Agent: The University Of British Columbia

20110196021 - High affinity nucleic acid ligands of complement system proteins: Methods are described for the identification and preparation of high-affinity Nucleic Acid Ligands to Complement System Proteins. Methods are described for the identification and preparation of high affinity Nucleic Acid Ligands to Complement System Proteins C1q, C3 and C5. Included in the invention are specific RNA ligands to C1q, C3... Agent: Gilead Sciences, Inc.

20110196022 - In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors: A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13... Agent: Biovec, LLC

20110196023 - In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors: A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13... Agent: Biovec, LLC

20110196024 - Injectable polydeoxyribonucleotide composition for the treatment of osteoarticular diseases: Composition based on polynucleotides extracted from natural sources for use in therapeutic treatment and/or as a therapeutic co-adjuvant in the treatment of degenerative diseases of the joints, in particular osteoarthritis.... Agent:

20110196020 - Treatment of chronic fatigue syndrome using selective agonists of toll-like receptor 3 (tlr3): A subset of human patients having chronic fatigue syndrome and impaired physical performance is treated using one or more different double-stranded ribonucleic acids (dsRNA) or other selective agonists of Toll-like receptor 3 (TLR3).... Agent:

20110195922 - Beta-l-2'-deoxy-nucleosides for the treatment of hepatitis b: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The... Agent: L'universite Montpellier Ii

20110195923 - Methods for predicting the response to anti-cancer treatment with an agonist of tlr7 or an agonist of tlr8: The present invention relates to methods for predicting the response to treatment with an agonist of TLR7, or an agonist of TLR8 or an anti-cancer agent for treating cancer, in particular non-small cell lung cancer comprising the step of detecting the expression of TLR7 or TLR8 in cancer cells of... Agent: Inserm (institiut National De La Sante Et De La Re Cherche Medicale)

20110195924 - Methods of inhibiting the interaction between s100p and the receptor for advanced glycation end-products: A method of inhibiting an interaction between a S100 protein and the receptor for advanced glycation end-products is provided comprising administering to a subject a therapeutically effective amount of cromolyn, C5, and/or other analogs, or salts, hydrates, or solvates thereof. In addition, provided herein are methods of treating a cancer... Agent:

20110195927 - Compositions comprising polymers having amino sugar units and methods of making and using same: Compositions comprise a polymer having units of an amino sugar, a polyol other than sorbitol, and boric acid, a salt thereof, or a combination thereof. Such compositions remain for an extended period in the eye and can be used for relief, treatment, or control of a condition of dry eye... Agent: Compositions Comprising Polymers Having Aminio Sugar Unites And Methods Of Making And Using Same

20110195926 - Purified beta glucan composition: The invention provides methods of using beta glucans to treat conditions associated with bone loss or low bone density as well as methods for promoting bone growth in situations where enhanced bone growth is desirable. In the invention methods beta glucans are administered so as to enhance the development of... Agent: Immudyne, Inc.

20110195925 - Sterile hyaluronic acid solutions: A process for sterilizing a solution comprising hyaluronic acid. The process comprises providing an aqueous solution of hyaluronic acid with a weight average molecular weight from 0.6 MDa to 3.6 MDa, and the concentration of the hyaluronic acid is from 0.04% to 0.8% by weight. The aqueous solution also has... Agent:

20110195928 - Administration of copper to an animal: The present invention is directed to the administration of copper to an animal using a composition containing copper dextran. A method is described for increasing the copper levels in an animal by the administration of a composition containing copper dextran. A preferred method of administration is intra muscularly. The use... Agent:

20110195929 - Compounds for the treatment of flaviviral infections: Described are various compounds and methods for the treatment of flaviviral infections. In particular, alkaloids and imino sugars in arabinose and/or lyxose stereochemical configuration with antiflaviviral activity are described.... Agent: Summit Corporation PLC

20110195930 - Pyridine derivative or its salt, pesticide containing it and process for its production: To provide a novel pesticide. The present invention provides a pesticide which contains, as an active ingredient, novel pyridine derivative represented by the formula (I) or its salt: wherein R1 is alkyl, cycloalkyl, alkoxyalkyl or OR3; R2 is 1H-1,2,4-triazol-1-yl which may be substituted, 1H-imidazol-1-yl which may be substituted, 1H-1,2,3-triazol-1-yl which... Agent: Ishihara Sangyo Kaisha, Ltd.

20110195931 - Methods and compositions for reducing neuronal cell death: Methods and compositions involving a class of boron-protected phenylphosphine agents having increased cell permeability and having improved chemical stability for treating or for preventing neuronal cell death-related diseases or conditions in a human or a non-human animal.... Agent: Wisconsin Alumni Research Foundation

20110195932 - Drug combinations for the treatment of duchenne muscular dystrophy: Combinations comprising (or consisting essentially of) one or more compounds of formula (1) with one or more ancillary agents, to processes for preparing the combinations, and to various therapeutic uses of the combinations. Also provided are pharmaceutical compositions containing the combinations as well as a method of treatment of Duchenne... Agent:

20110195933 - Pyrazolo[1,5-a]pyridines as mark inhibitors: The invention encompasses pyrazolo[1,5-a]pyridine derivatives which selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. Pharmaceutical compositions and methods of use are also included.... Agent:

20110195934 - Azolopyrrolone melanin concentrating hormone receptor-1 antagonists: e

20110195935 - Nitric oxide releasing amino acid ester compound, composition and method of use: There is provided amino acid ester compounds comprising at least one nitric oxide releasing group, pharmaceutically acceptable salts thereof and compositions thereof. These compounds involve an amino acid side-chain or an amino acid derivative thereof and a nitric oxide releasing group as depicted in the following structures: wherein R1 is... Agent:

20110195936 - Bicyclic sphingosine 1-phosphate analogs: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.... Agent: University Of Virginia Patent Foundation

20110195937 - Oxidized thiophospholipid compounds and uses thereof: m

20110195938 - Process for preventing or mitigating biofouling: Biofouling may be prevented or at least mitigated by employing a cinnamaldehyde additive to augment the affect of the conventional biocide. Exemplary cinnamaldehyde additives include, but are not limited to, cinnamaldehyde, cinnamic acid and cinnamyl alcohol. A cinnamaldehyde additive by itself, in some applications, may also inhibit biofouling.... Agent: Baker Hughes Incorporated

20110195939 - Antitumor properties of no modified protease inhibitors: HIV-protease inhibitors, particularly saquinavir, showed strong anticancer activity but numerous side effects limited its application. In order to overcome its toxicity original compounds were modified by covalent attachment of NO. The efficacy of parental and NO-modified drug was compared in vitro and in vivo. Anticancer activities of NO-modified saquinavir (Saq-NO)... Agent: Ganial Immunotherapeutics Inc.

20110195940 - Protease inhibitors having enhanced features: Provided herein (among other things) are protease inhibitor compounds having enhanced features, along with methods for administering such compounds. For example, the subject compounds can be administered without concomitant administration of a CYP3A4 inhibitor, have increased therapeutic index and/or increased potency, and are low-resistance inducing in nature. Exemplary potent HIV... Agent: Nektar Therapeutics

20110195941 - Methods of use to orally and topically treat acne and other skin conditions by administering a 19-nor containing vitamin d analog with or without a retinoid: Oral and topical pharmaceutical compositions, kits and methods of treatment thereof for treating various skin disorder including acne, psoriasis, ichthyosis, photoaging, photodamaged skin, and, skin cancer. Exemplary vitamin D analogs as active pharmaceutical ingredients include 2-methylene-19-nor-20(S)-1α-hydroxy-bishomopregnacalciferol, 19-nor-26,27-dimethylene-20(S)-2-methylene-1α,25-dihydroxyvitamin D3, 2-methylene-1α,25-dihydroxy-(17E)-17(20)-dehydro-19-nor-vitamin D3, 2-methylene-19-nor-(24R)-1α,25-dihydroxyvitamin D2, 2-methylene-(20R,25S)-19,26-dinor-1α,25-dihydroxyvitamin D3, 2-methylene-19-nor-1α-hydroxy-pregnacalciferol, 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol, (20R)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol, 2-methylene-19-nor-(20S)-1α-hydroxy-trishomopregnacalciferol, 2-methylene-23,23-difluoro-1α-hydroxy-19-nor-bishomopregnacalciferol, 2-methylene-(20S)-23,23-difluoro-1α-hydroxy-19-nor-bishomopregnancalciferol,... Agent:

20110195942 - Method of making and using 7alpha, 11beta-dimethyl-17beta-hydroxyestr-4-en-3-one 17-undecanoate: a

20110195943 - Napadisylate salt of 5-(2--1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one as agonist of the beta 2 adrenergic receptor: The present disclosure relates to crystalline monoapadisylate and/or heminapadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, and pharmaceutically acceptable solvates thereof. The present disclosure also relates to pharmaceutical compositions comprising the crystalline monoapadisylate and/or heminapadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, and to methods of treatment comprising these pharmaceutical compositions.... Agent:

20110195944 - Modified release emulsions for application to skin or vaginal mucosa: Modified release oil in water emulsions that delivers drugs to a target tissue. The emulsions according to the present invention contain the lipophilic active ingredient completely dissolved into the hydrophobic internal phase stabilised by a polymeric surfactant. The presence of this polymer around the hydrophobic droplets avoids the migration of... Agent: Polichem Sa

20110195945 - Compounds, compositions and methods for treating or preventing hypoxic or ischemic injury: Compositions and methods of treating or preventing disease or injury to a human patient or biological material undergoing ischemic or hypoxic conditions.... Agent: Ikaria, Inc.

20110195946 - High solid dispersions comprising biocides: The present invention relates to dispersions comprising a biocide selected from tralopyril, zinc pyrithione or tolylfluanid, or a combination of thereof, a polymeric surfactant, an anti-settling agent and one or more carrier liquids. These dispersions have a solids level up to 80% by weight and provide a zero-dust delivery system... Agent:

20110195947 - Methods of synthesizing and isolating n-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same: A method of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine (ABDNAZ) by reacting DNAZ with bromoacetyl bromide and boron trifluoride etherate to produce a mixture comprising ABDNAZ and a salt of DNAZ. Water and a solvent are added to the mixture to form an organic phase comprising the ABDNAZ and an aqueous phase... Agent: Alliant Techsystems Inc.

20110195948 - Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors: Compounds of Formula (I) in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor.... Agent: Array Biopharma Inc.

20110195949 - 2-benzothiophenyl- and 2-naphthyl-oxazolidinones and their azaisostere analogues as antibacterial agents: m

20110195950 - Organic compounds: in which R1 represents an optionally substituted aryl group or an optionally substituted heteroaryl group; R2 represents hydrogen or a substituent different from hydrogen; R3 represents an optionally substituted aryl group, cycloalkyl group, heteroaryl group, heterocyclyl group; X1 represents O, S, NR4, CR42; X2 represents O, S, NR4, CR42; X3... Agent: Novartis Ag

20110195951 - Diazaindole derivatives and their use in the inhibition of c-jun n-terminal kinase: The invention relates to diazaindole derivatives represented by the general formula (I): where A, E, G, R1, R2, R3 and R4 are defined herein, or pharmaceutically acceptable salts thereof, their use in the inhibition of c-Jun N-terminal kinase (JNK) activity, their use in medicine and particularly in the treatment of... Agent: Eisai R&d Management Co., Ltd.

20110195952 - Treating psychological conditions using muscarinic receptor m1 antagonists: Provided are methods of treating psychological diseases and conditions by administration of a preferential muscarinic acetylcholine receptor M1 antagonist, optionally with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist. The invention also provides for pharmaceutical compositions and kits for administration of at least one selective... Agent: Theracos, Inc.

20110195953 - Compositions and methods for treating cns disorders: The invention generally relates to thienopyridinone 5-HT4 receptor modulators, and in particular the use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with serotonin action, such as in treating Alzheimer's disease, cognition disorders, depression, and anxiety.... Agent: Epix Delaware, Inc.

20110195954 - Novel compounds: wherein U, V, X, Y, R1, R2, R3 and R4 are defined as mentioned in the description, the tautomers thereof, the isomers thereof, the diastereomers thereof, the enantiomers thereof, the hydrates thereof, the mixtures thereof and the salts thereof as well as the hydrates of the salts, particularly the physiologically... Agent: Boehringer Ingelheim International Gmbh

20110195956 - Heterocyclic kinase inhibitors: New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and... Agent:

20110195955 - Highly selective sigma receptor ligands: in which R1 can be a radical of an optionally substituted C-4 to C-7 N-containing heterocycle such as, for example, radicals of optionally substituted piperidines, optionally substituted piperazines, optionally substituted tetrahydropyridines, optionally substituted azepanes, tertiary amines (cyclic or acyclic), isoindoline-1,3-dione, or optionally substituted tetrahydroisoquinolones (aromatically substituted): R2,3,4,5,6 can each independently... Agent:

20110195958 - Activators of human pyruvate kinase: Disclosed are pyruvate kinase M2 activators, which are bis sulfonamide piperazinyl and piperidinyl compounds of Formula (I), 2,4-disubstituted 4H-thieno[3,2-c]pyrrole-2-(substituted benzyl)pyridazin-3(2H)-ones of Formula (II) and 6-(3,4-dimethylphenylaminosulfonyl)-3,4-dihydro-1H-quinolin-2-one of formula (III), wherein L, R1, R2, R11 to R16, R21 and R22 are as defined herein, that are useful in treating a number of... Agent: Us Dept. Of Health And Human Services

20110195957 - Substituted diazepan orexin receptor antagonists: The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the... Agent: Merck Sharp & Dohme Corp.

20110195959 - Compositions and methods relating to novel compounds and targets thereof: The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine compounds, and structurally and functionally related compounds, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation... Agent: The Regents Of The University Of Michigan

20110195960 - Inhibitors of c-fms kinase: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer,... Agent:

20110195961 - Tricyclic oxazolidinone antibiotic compounds: wherein Q is O or S and X is CH or N; and Y1, Y2 and Y3 may each be CH or N; and n is 0 when A is —CH2CH2CH(OH)— or —COCH2CH(OH)—, and n is 0, 1 or 2 when A is —(CH2)p—, p being 1, 2, 3 or... Agent: Actelion Pharmaceuticals Ltd.

20110195962 - Use of multi-pharmacophore compounds to treat nasal disorders: Compositions and methods for treating nasal disorders associated with nasal inflammation using a multipharmacophoric agent (MPA) that can prevent the production and/or release of at least one or more pro-inflammatory cytokines (for instance IL-1 and TNFα) and inhibit p38 MAP kinase or at least one matrix metalloproteinases (MMP-1 and MMP-9)... Agent: Alcon Research, Ltd.

20110195963 - Novel carbamoyloxy arylalkanoyl arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound: There is provided a novel carbamoyloxy arylalkanoyl arylpiperazine derivative compound having abundant racemic or enantiomeric characteristics, represented by the Formula 1, and pharmaceutically available salts or hydrates thereof. Also, there are provided a pharmaceutical composition for treating pain, anxiety or depression including an effective amount of the compound, and a... Agent:

20110195964 - Novel cyclic benzimidazole derivatives useful as anti-diabetic agents: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and... Agent:

20110195965 - Tetrahydro- and dihydroquinazolinones: The present invention relates to the use of tetrahydro- and dihydroquinazolinones of formula (I) as protein kinase activators or inhibitors, a method for their manufacture, their use for the preparation of a medicament for the treatment of diseases, their use for the manufacture of a pharmaceutical composition and new tetrahydro-... Agent:

20110195966 - Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor: The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound of formula (I) and (b) a mTOR inhibitor for the treatment of a target of rapamycin (mTOR) kinase dependent disease, especially a cancer disease; a pharmaceutical composition comprising such a combination; the use of such... Agent: Novartis Ag

20110195967 - 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them: Selected 2-arylacetic acids, their derivatives and pharmaceutical compositions that contain these compounds are useful in inhibiting chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from their activation.... Agent: Dompe Pha.r.ma S.p.a.

20110195968 - Thiazoles as fungicides: l

20110195969 - Amide compounds as boosters of antivirals: The present invention relates to compounds that have CYP450 inhibiting properties and are therefore useful as boosters of certain drugs, i.e. they are able to increase at least one of the pharmacokinetic variables of certain drugs when co-administered. The invention further provides the use of said compounds as improvers of... Agent:

20110195970 - Methods of identifying and treating responders to dopamine agonist therapy: The present invention is directed to a method of identifying patients to be treated by dopamine agonist therapy comprising the step of analyzing a plasma or urine sample from said patient for concentrations of norepinephrine (NE), norepinephrine metabolites (NE metabolites), dopamine, dopamine metabolites, serotonin, serotonin metabolites, or fasting triglycerides, wherein... Agent:

20110195971 - Methods of identifying responders to dopamine agonist therapy: The present invention is directed to a method of identifying patients to be treated by dopamine agonist therapy comprising the step of analyzing a plasma or urine sample from said patient for concentrations of norepinephrine (NE), norepinephrine metabolites (NE metabolites), dopamine, dopamine metabolites, serotonin, serotonin metabolites, or fasting triglycerides, wherein... Agent:

20110195972 - Application of 2,5 -dihydroxymethyl -3,6 - dimethyl pyrazine and its derivates in pharmacy: An application of 2,5-dihydroxymethyl-3,6-dimethyl pyrazine and its derivatives in the preparation of drugs for the treatment of, prevention of, and/or protection from heart failure wherein the structural formula of the compound is as follows:... Agent:

20110195973 - Cyclic substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity: The present invention relates to sodium channel blockers. The present Invention also includes a variety of methods of treatment using these inventive sodium channel blockers.... Agent: Parion Sciences, Inc.

20110195974 - Methods of treating inflammatory conditions with adrenergic antagonists: A method of treating inflammation and joint deterioration in mammals includes administering a therapeutically effective dose of alpha 1A receptor antagonists alone or in combination with a beta 2 adrenergic antagonists or beta 2 adrenergic antagonists and beta 2 adrenergic agonists.... Agent:

20110195975 - Materials and methods for suppressing and/or treating neurofibroma and related tumors: Germline mutations in the NF1 tumor suppressor gene cause Von Recklinghausen's neurofibromatosis type 1 (NF1), a common genetic disorder of the nervous system characterized by plexiform neurofibroma development. Using adoptive transfer of hematopoietic cells, we establish that NF1 heterozygosity of bone marrow derived cells in the tumor microenvironment is sufficient... Agent:

20110195976 - Compounds derived from 2-(3-methylenedioxy)-benzoyl indol: The present invention describes a series of derivatives of 2-(3-methylenedioxy)-benzoyl indol, their mixtures, their pharmaceutically acceptable salts, their enantiomers, pharmaceutical compositions comprising them, processes for preparing them, use in the prophylactic and/or curative treatment of sexual dysfunction. More specifically, the invention describes derivatives (R)-3-((2-(benzo[d][1,3]dioxol-5-carbonyl)-1H-indol-3-yl)methyl)-1-methylpiperazine-2,5-dione, and S)-3-((2-(benzo[d][1,3]dioxol-5-carbonyl)-1H-indol-3-yl)methyl)-1-methylpiperazine-2,5-dione.... Agent: Biolab Sanus Farmaceutica Ltda.

20110195977 - Acrylamido derivatives useful as inhibitors of the mitochondrial permeability transition: Acrylamido derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of the mitochondrial permeability transition pore (MPTP), such as the diseases characterized by ischemia/reperfusion, oxidative or degenerative tissue damage, are herein described. These compounds belong to the structural formula (I)... Agent:

20110195978 - Compounds for treatment of alzheimer's disease: Described herein are compounds, and pharmaceutical compositions, methods, and uses thereof for treating Alzheimer's disease.... Agent: Purdue Research Foundation

20110195979 - Compounds for the treatment and prevention of influenza: s

20110195980 - Bicyclic kinase inhibitors: New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and... Agent:

20110195981 - Methods and dosage forms for reducing side effects of benzisozazole derivatives: Disclosed are dosage forms and methods comprising benzisoxazole derivatives. More particularly, disclosed are dosage forms, methods, and new uses of benzisoxazole derivatives that substantially reduce or substantially eliminate certain side effects of the benzisoxazole derivatives when dosed to a patient.... Agent:

20110195983 - Quinazolinone derivatives useful as vanilloid antagonists: The present invention relates to the use of a quinazolinone compound of the formula (I) wherein R1, R2, R3, R4, R5 and m are as defined in the specification and in the claims, in free form or in salt form, and, where possible, in acid addition salt form, as a... Agent: Novartis Ag

20110195982 - Predictive marker for egfr inhibitor treatment: The present invention provides a biomarker that is predictive for the response to treatment with an EGFR inhibitor in cancer patients... Agent:

20110195984 - Pest control composition and pest control method: A pest controlling composition comprising, as active ingredients, a pyrimidine compound represented by Formula (1) and an anthranilamide compound represented by Formula (2).... Agent: Sumitomo Chemical Company, Limited

20110195985 - Compounds for the treatment of lysosomal storage diseases: A method of treating a lysosomal storage disease comprises administering a pyrimethamine derivative to a subject in need thereof.... Agent: The Hospital For Sick Children

20110195986 - Pyrrolone melanin concentrating hormone receptor-1 antagonists: Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression, anxiety... Agent: Bristol-myers Squibb Company

20110195987 - Treatment with cholinergic agonists: Methods of treating disorders with cholinergic agonists for example, muscarinic receptor agonists such as pilocarpine and cevimeline are provided. In particular, methods of treating and/or preventing interstitial cystitis, yeast infections, urinary tract infections, atrophic vaginitis, vaginal dryness, and sexual dysfunction associated with vaginal dryness by administering a cholinergic agonist to... Agent:

20110195989 - Controlled release formulations of opioids: Pharmaceutical formulations containing opioid components that each has a release profile. The components may provide immediate or controlled release of the opioid. The invention is also directed to methods of controlling release of one or more opioid compounds and methods of treating pain.... Agent:

20110195988 - Pharmaceutical composition: A liquid composition for administration to the buccal cavity of a patient comprising less than 10 mg/ml morphine and a pharmaceutically acceptable carrier... Agent: Special Products Limited

20110195990 - Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin: l

20110195991 - 3-aminoimidazo [1,2-a] pyridine derivatives as sglt inhibitors: Novel compounds of the formula I, in which X, Y, R, R′, R1, R1′, R1″, R2, R2′, R2″, R3, R3′, R4, R4′ and n have the meanings indicated in Patent Claim 1, are suitable as antidiabetics... Agent:

20110195992 - New compounds ii: and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial,... Agent: Proximagen Limited

20110195993 - Ppar agonist compounds, preparation and uses: d

20110195995 - Methods of optimizing treatment of estrogen-receptor positive breast cancers: Estrogen-receptor positive and progesterone-receptor positive breast cancer treatment can be optimized by determining the level of expression of genes in a breast sample from a human having an estrogen-receptor positive and progesterone-receptor positive breast cancer that identify a human with an increased likelihood of recurrence of the breast cancer.... Agent:

20110195994 - Piperidinyl gpcr agonists: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of diabetes and obesity.... Agent: Prosidion Limited

20110195996 - Transmucosal treatment methods in patients with mucositis: In accordance with the invention is an fentanyl-containing dosage form designed for transmucosal delivery which includes both an effervescent couple and a pH adjusting substance which can be administered to patients suffering from both pain and mucositis. Also provided is a method of treating pain in a patient having mild... Agent: Cephalon, Inc.

20110195997 - Dicarboxamide derivatives:

20110195999 - Novel antifungal agent containing heterocyclic compound: wherein A1 represents a 3-pyridyl group which may have a substituent, a quinolyl group which may have a substituent, or the like; X1 represents a group represented by the formula —NH—C(═O)—, a group represented by the formula —C(═O)—NH—, or the like; E represents a furyl group, a thienyl group, a... Agent:

20110195998 - Pest control agent: Disclosed is a compound usable as a pest control agent and has excellent pest control activity. A compound represented by formula (I) has excellent pest control activity. The compound or an agriculturally or horticulturally acceptable salt thereof is thus useful as a pest control agent.... Agent:

20110196000 - Use of succinate dehydrogenase (sdh) inhibitors in the treatment of plant species from the family of the true grasses: The use is described of at least one succinate dehydrogenase (SDH) inhibitor for increasing the biomass of the flag leaf, of leaf F-1 and/or of leaf F-2 of the plant of plant species from the family of the true grasses (Poaceae).... Agent: Bayer Cropscience Ag

20110196001 - Method to control insects resistant to common insecticides: N-Substituted sulfoximines are effective at controlling insects resistant to common insecticides.... Agent: Dow Agrosciences LLC

20110196002 - Diacylglycerol acyltransferase inhibitors: The present invention relates to isoxazole, thiazole and oxidiazole derivatives, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments, in particular to the use of these compounds in the prevention and treatment of diseases or disorders mediated by diacylglycerol acyltransferase (DGAT), particularly DGAT1.... Agent: Piramal Life Sciences Limited.

20110196003 - Tricyclic compound and pharmaceutical use thereof: e

20110196004 - Crystalline forms of (r) -5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz [z] ylidene] -2-( [z]-propylimino) -3-0-tolyl-thiazolidin-4-one: The invention relates to crystalline forms of (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one, processes for the preparation thereof, pharmaceutical compositions containing said crystalline forms, and their use as compounds improving vascular function and as immunomodulating agents, either alone or in combination with other active compounds or therapies.... Agent:

20110196005 - Antagonists of lysophosphatidic acid receptors: Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.... Agent: Amira Pharmaceuticals, Inc.,

20110196006 - Imazalil compositions comprising alkoxylated amines: The present invention relates to the use of alkoxylated amines to enhance the activity of fungicidal formulations comprising the fungicidal compound imazalil. It also relates to formulations comprising imazalil and alkoxylated amines. These formulations are useful to protect materials, plants, fruits or seeds against fungi.... Agent:

20110196007 - Monocyclic cyanoenones and methods of use thereof: The present invention features monocyclic cyanoenone compositions and methods for using the same in the treatment of diseases such as cancer, inflammatory diseases and neurodegenerative diseases.... Agent:

20110196008 - Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof: New polymorphs of Eltrombopag and Eltrombopag ethanolamine salt have been obtained and characterized. These polymorphs and pharmaceutical compositions comprising them are useful, for example, in treating conditions leading to thrombocytopenia.... Agent: Pliva Hrvatska D.o.o.

20110196009 - Inhibitors of akt activity: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.... Agent:

20110196010 - Crystalline chemotherapeutic: N-[4-(3-Amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea Hydrate Crystalline Form 1, ways to make it, formulations comprising it and made with it and methods of treating patients having disease using it are disclosed.... Agent: Abbott Laboratories

20110196011 - Substituted arylpyrazoles: [

20110196012 - Deuterated macrocyclic inhibitors of viral ns3 protease: This invention relates to novel macrocyclic protease inhibitors and their pharmaceutically acceptable salts thereof. This invention also provides compositions comprising at least one compound of this invention and the use of such compositions in methods of treating a flavivirus infection or liver fibrosis in a patient in need thereof.... Agent: Concert Pharmaceuticals, Inc.

20110196013 - Animal feed composition: The present invention relates to an animal feed composition that comprises free indole acetic acid (free IAA) or a derivative thereof. The invention also relates to a method for enhancing animal growth by feeding the animal with a composition according to the invention. The invention also relates to the use... Agent:

20110196014 - Methionine analogs and methods of using same: Provided are methionine analogs which may be useful for inhibiting protein synthesis, inhibiting microbial growth and/or treating infectious diseases. In some instances, the analogs exhibit bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and/or antiviral properties. Also provided are methods of treatment and methods of preparation, as well as kits and... Agent:

20110196015 - N 1-2-thiophene-2-ylethyl-n2-substituted biguanide derivate, preparation method thereof, and pharmaceutical composition containing the same as active ingredients: The present invention provides an N1-2-thiophen-2-ylethyl-N2-substituted biguanide derivative of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing same, and a pharmaceutical composition comprising same as an active ingredient. The inventive N1-2-thiophen-2-ylethyl-N2-substituted biguanide derivative exhibits improved blood glucose level- and lipid level-lowering effects even with a reduced... Agent: Korea Research Institute Of Chemical Technology

20110196027 - Beta-lactones as antibacterial agents: The present invention relates to specific beta-lactone compounds and compositions thereof for the treatment of infections, such as, e.g., infections with bacteria or infections with protozoa, in particular infections with Gram-positive and/or Gram-negative bacteria and of infectious diseases caused by or related to Gram-positive and/or Gram-negative bacteria, and to the... Agent: Ludwig-maximilians-universitat Munchen

20110196026 - Compositions and methods for preparation of poorly water soluble drugs with increased stability: The present invention provides stable pharmaceutical compositions of poorly water soluble pharmaceutical agents and stabilizing agents which function to increase stability of the compositions. The use of stabilizing agents provide extended stability of nanoparticle suspensions and other formulations of poorly water soluble pharmaceutical agents such as docetaxel under certain conditions,... Agent: Abraxis Bioscience, Inc.

20110196025 - Polymorphs of n-malonyl-bis(n'-methyl-n'-thiobenzoylhydrazide): At least 70% by weight of Compound 1 is the single crystalline form, Form A, Form C, or Form D, of the compound. A pharmaceutical composition comprises a pharmaceutically acceptable carrier or diluent, and compound 1, wherein at least 70% by weight of the compound is the single crystalline form,... Agent: Synta Pharmaceuticals Corp.

20110196028 - Pck activation as a means for enhancing sappa secretion and improving cognition using bryostatin type compounds: This invention provides a method for isolating and identifying proteins participating in protein-protein interactions in a complex mixture. The method uses a chemically reactive supporting matrix to isolate proteins that in turn non-covalently bind other proteins. The supporting matrix is isolated, and the non-covalently bound proteins are subsequently released for... Agent: Blanchette Rockefeller Neurosciences Institute

20110196029 - Composition for treating influenza a (h1n1) virus and a preparation method therefor: New pharmaceutical compositions extracted from Ferula assa-foetida are confirmed to effectively treat influenza A (H1N1) virus. The extraction method of the new pharmaceutical compositions mainly includes steps of (a) extracting F. assa-foetida with methanol to obtain a crude extract; (b) fractioning the crude extract with n-hexane-methanol to obtain a methanol... Agent: Kaohsiung Medical University

20110196031 - Compositions and methods for treating varicose veins: The present invention provides compositions and methods for preventing or treating diseases and disorders, the composition comprising vitamin C, vitamin E, and at least one of an omega-3 fatty acid and an omega-6 fatty acid.... Agent:

20110196030 - Tocotrienol esters: Esters of tocotrienols having pharmacological activities pertinent to the treatment of breast cancer and other forms of cancer are disclosed herein. Among those compounds is (Z)-4-oxo-4-((R)-2,5,7,8-tetramethyl-2-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl)chroman-6-yloxy)but-2-enoic acid. Tocotrienol esters were used to inhibit the growth and migration of +SA mammary epithelial cells and highly metastatic human breast cancer MDA-MB-231 cells... Agent:

20110196032 - Pharmaceutical dosage form of an antidepressant: The present invention relates to pharmaceutical dosage forms of an antidepressant. More particularly, the present invention relates to pharmaceutical dosage forms of Escitalopram oxalate. The present invention also relates to a process for the preparation of pharmaceutical dosage forms of Escitalopram oxalate.... Agent:

20110196033 - Prophylactic/ameliorating agent for adult diseases comprising 5-aminolevulinic acid, derivative of 5-aminolevulinic acid, or salt of 5-aminolevulinic acid or the derivative or 5-aminolevulinic acid as active ingredient: It is to provide a pharmaceutical composition which is different from an existing therapeutic agent of an adult disease, of a biochemical reaction-inhibiting type, and which action mechanism is to improve the basal metabolism, wherein the composition has no side effects, and does not generate drug resistance against adult disease;... Agent: Sbi Alapromo Co., Ltd.

20110196034 - Green garlic and methods of production: A new vegetable, referred to herein as green garlic, grown from garlic bulbils is disclosed. In particular examples, the green garlic is rich in one or more thiosulfinates. Methods of producing green garlic are also disclosed. In some examples, such methods permit year-round commercial production of green garlic.... Agent: Ophios, LLC

20110196035 - Temporally-controlled treatment of joint disease: A composition and method for treatment of osteoarthritis is disclosed. The composition includes at least one soluble injectable biocompatible carrier having a viscosity within prescribed limits and an amount of a calcium-channel blocker chosen in relation to the viscosity of the carrier. The concentration of the calcium-channel blocker in the... Agent:

20110196036 - Use of betaine: The present invention relates to use of betaine for protecting skin from biological irritation. The invention also relates to the use of betaine as a protecting agent in a cosmetic and/or toiletry preparation. The invention further relates to a method of protecting skin from biological irritation.... Agent: Danisco A/s

20110196038 - Bipolar trans carotenoid salts and their uses: The invention relates to trans carotenoid salt compounds, methods for making them, methods for solubilizing them and uses thereof. These compounds are useful in improving diffusivity of oxygen between red blood cells and body tissues in mammals including humans.... Agent: Diffusion Pharmaceuticals LLC

20110196037 - Use of nitrated lipids for treatment of side effects of toxic medical therapies: The present invention relates to methods of treating the side effects of a toxic medical therapy using nitrated lipids. In particular, the methods comprise the use of nitrated fatty acids or esters thereof to treat side effects, including organ system damage, caused by chemotherapy, radiotherapy, and the administration of other... Agent:

20110196039 - Controlled release arginine formulations: A sustained release formulation of L-arginine alone or in combination with an agent which enhances the biotransformation of L-arginine into NO is described herein. FIG. 1A shows a schematic representation of proposed L-arginine dependent and independent pahtways.... Agent:

20110196040 - Skin penetration enhancing systems for polar drugs: The invention relates to pharmaceutical compositions and related methods for the topical administration of polar drugs. In a particular embodiment, the invention relates to a pharmaceutical composition comprising an active pharmaceutical agent that is a polar drug, such as potassium 2,5-dihydroxybenzenesulfonate, at least one occlusive agent, and at least one... Agent: Action Medicines S.l.

20110196041 - Novel crystal form of calcium 3-acetylaminopropane-1-sulfonate: The present invention relates to a novel crystal form of calcium 3-acetylaminopropane-1-sulfonate, to a process for the preparation thereof, and to the use thereof in medicaments.... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20110196042 - Compositions and methods for influencing satiety, lipid metabolism, and fat utilization: The invention provides (1) genes differentially expressed in animals administered fatty acid amides that affect one or more of food intake, satiety, lipid metabolism, and fat utilization and (2) compositions and methods relating to the use of the genes to identify new compounds that affect one or more of food... Agent:

20110196043 - Methods and compositions for administration of trpv1 agonists: Compositions are provided that contain a TRPV1 agonist, such as capsaicin, and a solvent system. Topical application of the composition results in rapid delivery of agonist to the dermis and epidermis. Method of using the compositions for reducing nociceptive nerve fiber function in subjects, and for treatment of capsaicin-responsive conditions... Agent: Neurogesx, Inc.

20110196044 - Production of organic compound nanoparticles with high repetition rate ultrafast pulsed laser ablation in liquids: Disclosed is a method of producing a chemically pure and stably dispersed organic nanoparticle colloidal suspension using an ultrafast pulsed laser ablation process. The method comprises irradiating a target of an organic compound material in contact with a poor solvent with ultrashort laser pulses at a high repetition rate and... Agent:

20110196045 - Estrogenic compounds, process for their production and pharmaceutical uses thereof: in which the substituents have the meanings that are explained in more detail in the description, and pharmaceutical compositions containing them. The compounds of the invention are useful, for example, in hormone replacement therapies (HRT/ERT) and as contraceptives and estrogenic hormone therapies. Also provided is a process for synthesizing the... Agent:

20110196046 - Pigments: The present invention relates to pigments which comprise a substrate and an iron(II) silicate-containing coating applied thereto, to a process for the preparation of these pigments, and to the use thereof.... Agent: Merck Patent Gesellschaft Mit Beshrank Ter Haftung

  
08/04/2011 > patent applications in patent subcategories. inventions list

20110190192 - Methods for treating erectile dysfunction in patients with insulin-dependent diabetes: The present invention relates to the development of improved methods for treating erectile dysfunction associated with diabetes. Significantly, such dosing regimens can be combined with established methods for treating sexual dysfunction, including PDE5 inhibitors such as those sold under the trademark VIAGRA® to provide for significantly improved efficacy compared to... Agent: Cebix Inc.

20110190193 - Treatment of endothelial dysfunction in diabetic patients: A method for the treatment of endothelial dysfunction in a diabetic patient, including both diabetes induced macrovascular disorders and diabetes induced microvascular disorders, comprises administration, preferably parenteral administration, to the patient of an effective amount of high density lipoprotein (HDL).... Agent: Csl Limited

20110190195 - Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress: An antioxidant compound is disclosed. The compound is characterized by (a) a peptide including at least three amino acid residues of which at least two are cysteine residues, each having a readily oxidizable sulfhydryl group for effecting antioxidation; and at least two peptide bonds, each being cleavable by at least... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem

20110190194 - Preparation and composition of inter-alpha proteins from blood: The present invention generally provides processes for purification of Inter-alpha inhibitor proteins (IαIp) and compositions thereof from blood.... Agent: Pro Thera Biologics, LLC

20110190196 - Improved peptide mediators of cholesterol efflux: The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABAC1 that parallels that of full-length apolipoproteins. The invention also provides compositions comprising such polypeptides, methods of identifying, screening... Agent: The Regents Of The University Of California

20110190197 - Plant derived antibiotic peptide rich in glycine: The present invention relates to a novel peptide extracted from guava (Psidium guajava) seeds, that provides bactericide activity, Preferentially against Gram-negative bacteria which are known to cause urinary, hospital, and intestinal tract infections (Proteus sp. And Klebsiella sp.). The peptide, that has the amino acid sequence RESPSSRMEC YEQAERYGYG GYGGGRYGGG YGSGRGQPVG... Agent: Empresa Brasileira De Pesquisa Agropecuaria - Embrapa

20110190198 - Peptide sequnces, their branched form and use thereof for antimicrobial applications: The present invention relates to an antibacterial peptide having from the amino to the carboxylic terminal an amino acid sequences selected from the group of: KKIRVRLSA, SEQ ID NO. 1, RRIRVRLSA, SEQ ID NO. 2, KRIRVRLSA, SEQ ID NO. 3, RKIRVRLSA, SEQ ID NO. 4 or a derivative thereof and... Agent: Universit&#xc0 Degli Studi Di Siena

20110190199 - Combination therapy for tuberculosis: The present invention relates to methods of treating tuberculosis, including multi-drug resistant varieties and latent tuberculosis. More particularly, the present invention relates to a method of treating tuberculosis in a mammal comprising administering to said mammal in need thereof an effective amount of a compound of formula (I), (S)—N-[[3-[3-fluoro-4-(4-thiomorpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide, or... Agent: The Johns Hopkins University

20110190200 - Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers: Modified glucagon peptides are disclosed having improved solubility and/or half-life while retaining glucagon agonist activity. The glycogen peptides have been modified by substitution of native amino acids with, and/or addition of, charged amino acids to the carboxy terminus of the peptide. The modified glucagon agonists can be further modified by... Agent:

20110190201 - Method, device, and kit for maintaining physiological levels of steroid hormone in a subject: A method, device, or kit is provided which maintain a substantially physiological cyclic pre-menopausal level of one or more steroid hormones in a mammalian subject in need thereof. The method, device, or kit includes providing to the subject at least one treatment regimen including replacement therapy for the one or... Agent: Searete LLC

20110190202 - Prevention of cellular senescence in mammals by natural peptide complexes: Preventing skin aging by targeting multiple causes by a single bullet is of primal scientific and consumer interest. A treatment based on compositions of compound (I) for cellular senescence to control cellular degradation offers such a solution to multiple skin ailments including skin degradation from cancer, diabetes, radiation treatments, chemotherapy,... Agent: Island Kinetics Inc.

20110190203 - Ophthalmic compositions containing a synergistic combination of two polymers: Ophthalmic compositions suitable for use as artificial tears or as vehicles for ophthalmic drugs are disclosed. The compositions contain a combination of two polymers that have a synergistic effect on viscosity.... Agent: Alcon, Inc.

20110190204 - Taxane- and taxoid-protein compositions: Compositions comprising a taxane or taxoid, such as paclitaxel, and a protein, such as albumin or a metal-transferrin, such as gallium-transferrin, can be prepared by combining an aqueous protein solution with a second solution containing the taxane or taxoid, a non-ionic surfactant, and an alcohol; adjusting the pH of the... Agent: Oncbiomune, L.L.C.

20110190205 - Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (glp)-1 compound or a melanocortin-4 receptor (mc4) agonist peptide: The present application relates to novel compounds, methods and formulations useful for the oral delivery of a glucagon like peptide-1 compound or a melanocortin 4 receptor agonist peptide.... Agent: Emisphere Technologies, Inc.

20110190206 - Reducing myocardial reperfusion injury by the combination therapy of protein kinase a activation and b1-adrenergic receptor blockade: Embodiments of the invention are directed to methods of treating reperfusion or resuscitation injury in an individual in need of such treatment, comprising the step of administering to the individual who has had, having, or is at immediate risk of having an ischemic event an amount of a composition comprising... Agent: The Board Of Regents Of The University Of Texas System

20110190207 - Inhibiting binding of fgf23 to the binary fgfr-klotho complex for the treatment of hypophosphatemia: The present invention is directed to a method of treating hypophosphatemia in a subject. This method involves selecting a subject with hypophosphatemia associated with elevated or normal FGF23 and administering to the selected subject an inhibitor of FGF23-Klotho-FGF receptor complex formation under conditions effective to treat the hypophosphatemia. The present... Agent: New York University

20110190208 - Medical use of the radical scavenger and antioxidant alpha-1-microglobulin: Medical use of alpha-1-microglobulin (A1M) in the treatment or prophylaxis of diseases wherein oxidative stress is a responsible factor in the progress of the disease. Notably, the present invention relates to the medical use of alpha-1-microglobulin in the treatment or prophylaxis of diseases or conditions associated with the presences of... Agent:

20110190209 - Conjugates having a releasable linkage: The present invention provides conjugates having a releasable linkage. Methods of making conjugates, and methods for administering conjugates, are also provided.... Agent: Nektar Therapeutics

20110190210 - Prominin-1 peptide fragments and uses thereof: Described herein are peptide compositions of a prominin-1, which have regenerative activity. As such the peptides are useful when regeneration is needed, for example, to enhance angiogenesis, increase VEGF binding to endothelial cells, promote vasodilation, enhance cell migration, enhance cell proliferation, stimulate neuronal growth, prevent neurodegeneration, and/or promote neuroregeneration.... Agent: Children's Medical Center Corporation

20110190211 - Cyclopentaquinazoline derivatives for the treatment of rheumatoid arthritis or acute myeloid leukaemia: A cyclopenta[g]quinazoline derivative, containing an L-Glu-γ-D-Glu dipeptide group, of formula (I): wherein R1 is amino, C1-4 hydroxyalkyl, C1-4 fluoroalkyl or methoxy-C1-4-alkyl; R2 is hydrogen, C1-4 alkyl, C3-4 alkenyl, C3-4 alkynyl, C2-4 hydroxyalkyl C2-4 halogenoalkyl or C1-4 cyanoalkyl; and Ar is phenylene, thiophenediyl, thiazolediyl, pyridinediyl or pyrimidinediyl which may optionally bear... Agent:

20110190212 - Cyclic tetrapeptides: Cyclic tetrapeptides that are kappa opioid receptor (KOR) antagonists can be used in therapeutic applications for treating, inhibiting, and/or preventing drug addiction, drug use, or drug seeking behavior in a subject. This can include subjects that have a history of drug addiction. The drug can be selected from cocaine, alcohol,... Agent: University Of Kansas

20110190214 - Advantageous salts of mu-opiate receptor peptides: The subject invention provides advantageous new salts of mu-opiate receptor peptides. These salts have been found to have excellent properties in terms of their crystal structure, stability, solubility, lack of impurities and/or the ability to be produced, with these advantageous properties, in amounts sufficient for the production of therapeutic compositions.... Agent:

20110190216 - Materials and methods for treatment of spinal muscular atrophy and taxane-induced peripheral neuropathy (tipn): The present invention concerns materials and methods for treating, inhibiting the progression or, and/or preventing a disorder associated with and/or characterized by neuronal degeneration, such as SMA or TIPN, in a person or animal. One aspect of the invention pertains to a fusion protein comprising: i) an SMN polypeptide portion,... Agent: Florida State University Research Foundation

20110190213 - Retro-inverso peptides derived from interleukin-3: The invention provides methods of treatment using retro-inverso peptides derived from interleukin-3 (IL-3) having between 12 and about 40 amino acids and including the sequence that is retro-inverso with respect to SEQ ID NO: 1. The peptides of the invention have the same activity as native IL-3 and also have... Agent: Myelos Corporation

20110190215 - Therapeutic use of peptides: The amino acid sequences of peptides are disclosed. These peptides, and combinations thereof, are useful, inter alia, for the treatment of obesity, type II diabetes mellitus, hypertension, central nervous system disorders, dementia, Alzheimer's disease, asthma, and cancer,... Agent:

20110190217 - Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic epo short peptides: The described invention provides methods for treating an inflammatory brain disease, disorder or condition and for treating a traumatic brain injury having an inflammatory component in a subject in need thereof using isolated erythropoietin (EPO)-derived oligopeptides.... Agent:

20110190218 - Bag-1 peptide that inhibits prostate cancer: The present invention relates to a polypeptide having antitumor properties, to a vector encoding said polypeptide, to a host cell containing said vector, to uses of said polypeptide in the manufacture of a medicament for the treatment of cancer in patients, to a method comprising binding said polypeptide to molecular... Agent: Karlsruhe Institute Of Technology

20110190219 - Treating cancer with granulocyte-macrophage colony stimulating factor: Methods for treating cancer (e.g., metastatic cancer to the lung or chronic lymphocytic leukemia) in patients are described that include administrating an aerosolized granulocyte macrophage colony stimulating factor to the patients. Methods for stimulating an immune response in patients also are described.... Agent:

20110190220 - Use of defensin alpha 1 and/or defensin alpha 4, as a marker for predicting treatment response and/or a relapse in a patient suffering form chronic myeloid leukemia: The present invention pertains to the use of defensin α1 and/or defensin α4, as a marker for predicting and following the response of a patient suffering from chronic myeloid leukaemia to a treatment with imatinib.... Agent:

20110190221 - Modulation and repletion/enhancement of the complement system for treatment of trauma: The present invention features the use of selected complement activation inhibitor(s) for treating an individual who has suffered a severe injury. The complement activation inhibitor acts at or above the level of C3 activation and does not significantly deplete or irreversibly inhibit complement activation. Also provided are compositions and methods... Agent: Apellis Ag

20110190222 - Selective inhibition of polyglutamine protein expression: The present invention relates to the selective inhibition of protein expression of CAG repeat-related disease proteins such as Huntingtin using nucleic acid analogs. Peptide nucleic acids and locked nucleic acids are particularly useful analogs.... Agent:

20110190223 - Hemcm42 nucleic acids: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing... Agent: Human Genome Sciences, Inc.

20110190224 - Non-viral delivery of compounds to mitochondria: A conjugate comprises: (a) a mitochondrial membrane-permeant peptide; (b) an active agent or compound of interest such as a detectable group or mitochondrial protein or peptide; and (c) a mitochondrial targeting sequence linking said mitochondrial membrane-permeant peptide and said active mitochondrial protein or peptide. The targeting sequence is one which... Agent:

20110190227 - Antagonists of prostaglandin d2 receptors: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists Of PGD2 receptors. Also described herein are methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating... Agent: Amira Pharmaceuticals, Inc.

20110190226 - C4'-substituted-2-deoxyadenosine analogs and methods of treating hiv: The invention provides for novel 2-Deoxyadenosine compounds, which can treat HIV infection at low cytotoxicity values. Substitution at the 4′-position provided compounds which demonstrated low cytotoxicity values in an ATP-based cytotoxicity assay.... Agent:

20110190225 - Topical method for prompt relief of severe ascites: A means is provided to make the capsules of cirrhotic or fibrotic livers relatively impermeable to liver tissue fluid or lymph in humans or other mammals suffering from severe chronic ascites or refractory ascites by application of collodion. The means will be useful to decrease the need for liver and... Agent:

20110190230 - Betalain compositions and uses thereof: Contemplated compositions and methods employ betalains for treatment of various conditions, and especially osteoarthritis, sinusitis, contact dermatitis, acne, an allergic condition, reduced mental alertness, reduced physical strength, reduced physical endurance, and/or impaired mood.... Agent:

20110190229 - Compounds, compositions and methods for preventing skin darkening: A method for preventing hyperpigmented skin, undesired pigmentation disorder of skin, or undesired darkening of skin using coumarin compounds, the use of such compounds, and compositions and formulations thereof are disclosed. In a particular embodiment, the coumarin compounds are selected from robustic acid methyl ether, scandenin, and coumophos. The compounds... Agent:

20110190228 - Sanitising compositions: The present invention relates to a sanitising composition, particularly to a sanitising composition for combating undesired microorganisms, especially those present on food products such as salads, poultry, cut fruit, and in hospital environments. There is provided a sanitising composition comprising at least one flavonoid, and at least one a surfactant,... Agent:

20110190231 - Thioamide compounds, method of making and method of using thereof: e

20110190232 - Insecticidal combinations: A method of controlling or preventing damage to a plant, which comprises applying on the plant or a surrounding area thereof a combination comprising (I) abamectin, and (II) cyflumetofen, in any desired sequence or simultaneously.... Agent: Syngenta Crop Protection LLC

20110190233 - Anionic conjugates of glycosylated bacterial metabolite: The invention relates to anionic conjugates of glycosylated bacterial metabolites that may be used to mimic the structure and/or activity of the anionic bioactive molecules known as glycosaminoglycans (GAGs). The invention also relates to processes for the preparation of the conjugates. Such conjugates are useful in the prophylaxis and/or treatment... Agent: Glycan Biosciences Pty Ltd

20110190372 - Compositions and methods for treating inflammatory disorders: Compositions and methods for antagonizing miRNAs that are overexpressed in chronic, non-healing wounds, as compared to healthy tissue, are disclosed. The miRNA antagonists are oligonucleotides that hybridize to selected pre-miRNA or mature miRNAs and prevent the miRNAs from binding to and downregulating their target mRNAs. Methods of using the miRNA... Agent: New York University

20110190375 - Compositions comprising cmyc sirna and methods of use thereof: The present invention provides nucleic acid molecules that inhibit c-Myc expression. Methods of using the nucleic acid molecules are also provided.... Agent: Intradigm Corporation

20110190383 - Diagnostic, prognostic and therapeutic uses of mirs in adaptive pathways and/or disease pathways: Described herein are methods and compositions for the diagnosis, prognosis and treatment of various adaptive and/or of disease pathways by examining samples containing one or more miRs therein, and by formulating therapeutic agents therefrom.... Agent: The Ohio State University

20110190371 - Genetic suppression and replacement: Methods and agents for suppressing expression of a mutant allele of a gene and providing a replacement nucleic acid are provided. The methods of the invention provide suppression effectors such as, for example, antisense nucleic acids, ribozymes, or RNAi, that bind to the gene or its RNA. The invention further... Agent: Optigen Patents Limited

20110190377 - Method for producing a cell and/or tissue and/or disease phase specific medicament: t

20110190373 - Methods and compositions for the treatment or prevention of pathological cardiac remodeling and heart failure: The invention relates to methods of treating or preventing pathological cardiac remodeling and/or preventing heart failure. These methods include the administration of a PDE1 inhibitor to a patient under conditions effective to treat or prevent pathological cardiac remodeling, and therefore heart failure that occurs as a result of such remodeling.... Agent: University Of Rochester

20110190380 - Methods for delivery of sirna to bone marrow cells and uses thereof: The present invention relates to a method for the delivery of therapeutic oligonucleotides to bone marrow, and in particular delivery of siRNA to a subset of bone marrow cells. The method comprises systemically administering siRNA to a subject in need thereof, to reduce or inhibit expression of a gene associated... Agent:

20110190374 - Methods of treating a meiotic kinesin associated disease: The invention provides methods of treating a meiotic kinase-associated disease, preferably the meiotic kinase HSET, by administering an inhibitor of the meiotic kinase. Preferably, the disease is associated with the presence of supernumerary centrosomes, such as cancer. Methods of inhibiting the growth of a tumor cell by contacting the cell... Agent: Dana-farber Cancer Institute, Inc.

20110190378 - Mir 204, mir 211, their anti-mirs, and therapeutic uses of same: Embodiments of the invention provide methods of preventing or treating detrimental epithelial cell proliferation, loss of epithelial cell differentiation, age-related macular degeneration and/or proliferative vitreal retinopathy in an individual comprising administering to an individual in need thereof an effective amount of miR 204, an effective amount of miR 211, or... Agent: Usdh, Nih

20110190370 - Modulation of hif1(alpha) and hif2(alpha) expression: Compounds, compositions and methods are provided for modulating the expression of HIF1α and/or HIF2α. The compositions comprise oligonucleotides, targeted to nucleic acid encoding HIF1α and HIF2α. Methods of using these compounds for modulation of HIF1α and/or HIF2α expression and for diagnosis and treatment of disease associated with expression of HIF1α... Agent: Isis Pharmaceuticals, Inc.

20110190379 - Plant pathogen resistance: The present invention relates to a method for protecting a plant from infection by a pathogen by decreasing the presence of a plant hormone or reducing the responsiveness of a plant to a plant hormone. In particular, the invention related to infection by a necrotrophic pathogen, such as Fusarium Head... Agent:

20110190381 - Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma: RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.... Agent: Alcon Inc.

20110190376 - Rnai-related inhibition of tnfa signaling pathway for treatment of macular edema: RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having or at risk of developing macular... Agent: Alcon Research, Ltd.

20110190382 - Treatment of cancer by inhibition of igfbps and clusterin: Agents that reduce the amount of IGFBP-2 and/or IGFBP-5 and that are known to be useful in the treatment of cancer result in increased expression of the protein clusterin. Since clusterin can provide protection against apoptosis, this secondary effect detracts from the efficacy of the therapeutic agent. In overcoming this,... Agent: The University Of British Columbia

20110190386 - Aptamer inhibitors of osteopontin and methods of use thereof: The present invention polynucleotide aptamers that selectively bind to and inhibit the function of osteopontin, pharmaceutical compositions comprising the same, and methods of use for diagnostics and treatment of diseases and disorders associated with osteopontin.... Agent:

20110190385 - Methods and products for reawakening retrocyclins: Products and methods are provided for the restoring the endogenous expression of theta-defensins, such as retrocyclin-1, in mamallian cells. The present invention also includes products and methods for inhibiting sexually transmitted virus entry, e.g., HIV-1 virus entry, into a mammalian cell via, for example, administering to a subject an amount... Agent:

20110190384 - Sirna specific to wt1 17aa(-)isoform and use thereof: Disclosed is a polynucleotide having at least 15 contiguous bases in the base sequence of SEQ ID NO:26 and including the base sequence of SEQ ID NO:27. Also disclosed is siRNA produced based on the polynucleotide. By means of this, a cancer cell-specific molecular-targeted therapy, which successfully controls the function... Agent:

20110190234 - Mycobacterium membrane protease as a target for inhibitors of intrabacterial ph homeostasis: The present invention is directed to methods and compounds for inhibiting bacterial growth and treating a bacterial infection in a subject. These methods involve providing an inhibitor of intrabacterial pH homeostasis, including inhibitors of the Mycobacterium tuberculosis Rv3671c gene encoded membrane protease. Methods for identifying novel compounds that disrupt intrabacterial... Agent: Cornell University

20110190235 - Boron-containing small molecules as antiprotozoal agents: This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.... Agent: Anacor Pharmaceuticals, Inc.

20110190236 - Chemical compounds: The present invention features compounds that are prodrugs of HIIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.... Agent: Glaxosmithkline LLC

20110190237 - Macrocyclic prodrug compounds useful as therapeutics: The present invention includes macrocyclic prodrug compounds, pharmaceutical compositions containing them. The present invention also includes use of these compounds in the treatment of various diseases including an autoimmune disease, an inflammatory disease, a neurological or neurodegenerative disease, cancer, a cardiovascular disease, allergy, asthma, a hormone-related disease, and tumors or... Agent: Universite De Strasbourg

20110190238 - Modifications of solid 3-sn-phosphoglycerides: Methods for hydrolyzing solid ungranulated lysophosphatidylcholine with phospholipase A2 are provided. Also disclosed are methods for making a lipid matrix of lysophosphatidylcholine, monoglyceride and fatty acid, and lipid matrices of particular structure.... Agent: Biomolecular Products, Inc.

20110190239 - Bmi-1 protein expression modulators: The compounds, pharmaceutical compositions, and methods of using such compounds or compositions thereof described herein are useful for treating a disease modulated by B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein expression.... Agent: Ptc Therapeutics, Inc.

20110190240 - Nuclear factor kappa b pathway inhibitor composition and use of same: An embodiment of the invention provides a pharmaceutical composition comprising a compound of formula (I)a pharmaceutically acceptable salt, prodrug, hydrate, or solvate thereof. Another embodiment of the invention provides a method of treating or preventing a condition associated with increased expression and/or activity of an NFκB pathway using same compounds.... Agent: The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services

20110190241 - Targeting an hiv-1 nef-host cell kinase complex: Drug candidates for inhibition of HIV-I replication can target Src family kinases (SFK), such as Hck, that interact with Nef protein of the virus. Compounds characterized by such inhibitory activity were identified via an assay for kinase activity of an SFK in a Nef:SFK complex. Illustrative of inhibitors identified using... Agent:

20110190242 - Compositions and methods for the treatment of inflammatory disease: The invention relates to methods of treating inflammatory disease comprising administering a compound of formula A, a compound of any one of formulae 1-49 or I-III, a lipoxin compound, or an oxylipin compound.... Agent: Resolvyx Pharmaceuticals, Inc.

20110190243 - Diagnosis and treatment of back pain: The present invention relates to methods of diagnosing and/or treating lower back pain (LBP). In one embodiment, the invention relates to a system for diagnosis of a form of lower back pain in an individual, using a means to identify a type and/or a concentration of one or more inflammatory... Agent: Virginia Mason Medical Center

20110190248 - Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them: the tautomers, the stereoisomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for the treatment of diseases, particularly tumoral diseases as... Agent: Boehringer Ingelheim International Gmbh

20110190247 - Cyclopropylchromene derivatives as modulators of the alpha-2c receptor: In its many embodiments, the present invention provides a novel class of cyclopropylchromene derivatives as modulators of a2C adrenergic receptor, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition,... Agent: Schering Corporation

20110190246 - Estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring: The present invention is directed to novel pyrazolo-estrien and triazolo-estrien-derivatives, pharmaceutical compositions containing them and their use in the treatment or prevention of disorders and diseases mediated by an estrogen receptor such as hot flashes, vaginal dryness, osteopenia, osteoporosis, hyperlipidemia, loss of cognitive function, degenerative brain diseases, cardiovascular diseases, cerebrovascular... Agent: Bayer Schering Pharma Aktiengesellschaft

20110190244 - Method of treatment of egfr inhibitor toxicity: e

20110190245 - Nanosuspension with antifungal medication to be administered via inhalation with improved impurity profile and safety: The present invention is directed to new nanosuspensions of antifungal azole derivatives, particularly itraconazole, with with improved impurity profile optimized for inhaled administration for the prevention, reversal and medical treatment of fungal infections of the respiratory tract including adjacent lymph nodes. The new formulation which is devoid of particulate inorganic... Agent:

20110190249 - Therapeutic methods and uses of sapogenins and their derivatives: The invention discloses therapeutic methods and uses of certain steroidal sapogenins, related compounds and derivatives thereof, in the treatment of non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, motor-sensory neurodegeneration or receptor dysfunction or loss in the absence of cognitive, neural and neuromuscular impairment.... Agent: Phytopharm PLC

20110190250 - Eye drop with difluprednate for macular edema treatment: The present invention aims to provide an eye drop for treating macular edema. The present invention provides an eye drop for treating macular edema, which contains difluprednate as an active ingredient. The eye drop can afford effects such as improvement of visual acuity and decreased foveal retinal thickness in macular... Agent: Yamagata University

20110190251 - Method for inhibiting the build-up of arterial plaque by administering fullerenes: Disclosed herein are methods of inhibiting the build-up of arterial plaque in a subject in need thereof. These methods comprise administering to the subject in need thereof a therapeutically effective amount of fullerenes.... Agent:

20110190252 - Compositions including clavulanic acid and related methods of use: Methods of treating a disorder in a subject comprising administering to a subject an elastase inhibitor such as clavulanic acid, sulbactam, or tazobactam are described.... Agent:

20110190254 - Cephalosporin having catechol group: t

20110190253 - Method for treating tuberculosis: The present invention generally relates to methods for treating tuberculosis in a subject comprising administering to the subject an antibiotic in conjunction with clavulanic acid or salt thereof. The antibiotic can be carbapenem (e.g., meropenem or imipenem) or cefuroxime. The present invention also relates to related pharmaceutical compositions and methods... Agent:

20110190258 - Aryl benzylamine compounds: The present invention relates to substituted aryl-benzylamine compounds, to processes for their production, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.... Agent: Novartis Ag

20110190257 - Bicyclic heterocycles as mek kinase inhibitors: The invention relates to bicyclic heterocycles of formulae I and II with anti-cancer and/or anti-inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth, treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention... Agent: Genetech, Inc.

20110190259 - Compounds and compositions as protein kinase inhibitors: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion... Agent: Irm LLC

20110190261 - Mapk/erk kinase inhibitors: e

20110190260 - Novel compounds useful for the treatment of degenerative and inflammatory diseases: [1,2,4]Triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone... Agent:

20110190256 - Amine and ether compounds which modulate the cb2 receptor: Compounds which modulate the CB2 receptor are disclosed. The compounds are useful for treating CB2 receptor-mediated diseases such as pain.... Agent: Boehringer Ingelheim International Gmbh

20110190255 - Heterocyclic compounds: W is CH2, O, or NH; and R1, R2, R3, R4, R5, R6, m, n, t, and x are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing,... Agent: Bristol-myers Squibb Company

20110190266 - 5,6,6a,7,8,9-hexahydro-2h-pyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp): wherein the variables Y, Z, A, B, R1, R2, R3, R1′, R2′, R3′, R4 and R5 are as defined herein and methods of their synthesis. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein... Agent:

20110190262 - Aryl-and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use: wherein the groups R1 to R3, X, m, n and o are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme,... Agent: Boehringer Ingelheim International Gmbh

20110190264 - Compounds and compositions as kinase inhibitors: The invention relates to triazine and pyrimidine derivatives having Formula (1) or (2), and methods for using such compounds. For example, the compounds of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, c-ros oncogene (ROS), insulin-like... Agent: Irm LLC

20110190263 - Compounds and compositions as modulators of gpr119 activity: The invention provides compounds of Formula (I): pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.... Agent: Irm LLC

20110190265 - Methods and compositions for treating bacterial infections by inhibiting quorum sensing: The present invention provides methods for treating bacterial infections in a subject comprising administering to the subject a sub-growth inhibiting amount of a 5′-Methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) inhibitor. The present invention further provides pharmaceutical compositions comprising a sub-bacterial-growth inhibiting amount of a 5′-Methylthioadenosine/S-adenosyl homocysteine nucleosidase (MTAN) inhibitor and a pharmaceutically... Agent:

20110190267 - Prodrugs of opioids and uses thereof: The present invention concerns prodrugs of opioid analgesics and pharmaceutical compositions containing such prodrugs. Methods for providing more consistent pain relief by increasing the bioavailability of the opioid analgesic with the aforementioned prodrugs are provided. The invention also provides for decreasing the adverse GI side effects of opioid analgesics.... Agent: Shire Pharmaceuticals, Inc.

20110190268 - Novel benzimidazole linked pyrrolo[2,1-c[1,4] benzodiazepine hybrids as potential antitumour agents and process for the preparation thereof: The present invention provides a compounds of general formula (8), (11) and (14), useful as potential antitumour agents against human cancer cell lines. The present invention further provides a process for the preparation of pyrrolo [2,1-c][1,4]benzodiazepine hybrids of general formula (8), (11) and (14).... Agent:

20110190269 - Gamma secretase modulators: wherein R1, R1′, R2, R3, n, A, and hetaryl are defined herein or to pharmaceutically active acid addition salts thereof. The present compounds of formula I are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of... Agent:

20110190271 - 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents: The present invention provides 2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferative diseases such as tumorigenic cancers.... Agent: Rigel Pharmaceuticals, Inc.

20110190272 - Chemical compounds: The invention relates to chemical compounds of formula (I): or pharmaceutically acceptable salts thereof which possess CSF-IR kinase inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of... Agent: Astrazeneca Ab

20110190273 - Methods and compositions in the treatment of coronaviruses: The invention relates generally to the field of virology, and relates to the identification and characterization of the targets involved in the evasion strategy of viruses and to the use thereof in methods to identify anti-viral compounds. More in particular to identify compounds which are modulators of myosin light chain... Agent: Universiteit Gent

20110190270 - Methods of treating thromboembolic disorders: The field of the invention relates to methods for dissolving a thrombus using inhibitors of platelet contractility. More particularly, the present invention relates to the use of an inhibitor of platelet contractility in combination with one or more thrombolytic agents and optionally one or more anticoagulants for inhibiting platelet contraction... Agent: Monash University

20110190274 - Salt of, and processes for the preparation of, 1-isopropyl-4-hexahydro-1h-1,4-diazepine: The invention relates to 1-isopropyl-4-{[4-(tetrahydro-2H-pyran-4-yloxy)phenyl]carbonyl}hexahydro-1H-1,4-diazepine mono-maleate, and crystalline Form 1 thereof.... Agent: Glaxo Group Limited

20110190275 - C2-fluoro substituted piperazine linked pyrrolo[2,1-c][1,4] benzodiazepine dimers and a process for the preparation thereof: The present invention provides a compounds of general formula IXa-d, useful as potential antitumour agents and pharmaceutical composition comprising these compounds exhibits binding affinity with calf thymus (CT) DNA at a molar ratio of 1:5 in aqueous sodium phosphate buffer at pH of 7.00. The present invention further provides a... Agent:

20110190276 - Pyridine derivatives and their use in the treatment of psychotic disorders: A method of treatment of anxiety disorders which comprises administering to a host in need thereof an effective amount of a compound of formula (I):... Agent:

20110190277 - Pharmaceutical combination for the prevention or treatment of cardiovascular, cardiopulmonary, pulmonary or renal diseases: A method for the prevention or treatment of a cardiovascular, cardiopulmonary, or renal disease or condition in a human or mammal patient, the method comprising administering to the patient in need thereof an effective amount of: (a) telmisartan or a polymorph or salt thereof; and (b) simvastatin.... Agent: Boehringer Ingelheim International Gmbh

20110190278 - Bicyclic heterocyclic derivative: [wherein R1a is halogen, etc.; R1m is H, etc.; G1 is —N(R1b)—, etc.; G2 is —CO—, etc.; G3 is —C(R1c)(R1d)—, etc.; G4 is oxygen, etc.; R1b is optionally substituted C1-6 alkyl, etc.; R1c and R1d are independently the same or different, H, etc.; R3 is H, optionally substituted C1-6 alkyl,... Agent: Dainippon Sumitomo Pharma Co.

20110190279 - Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity: h

20110190280 - Thiazole and oxazole kinase inhibitors: The present invention provides thiazole and oxazole compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.... Agent:

20110190281 - Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis: This invention relates to novel sulfone 2I3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyper-proliferative and/or angiogenesis mediated disorders, as a sole agent or in combination with other... Agent: Bayer Schering Pharma Aktiengesellschaft

20110190282 - Novel vegf-2 receptor and protein tyrosine kinase inhibitors and pharmaceutical use thereof: The invention relates to compounds of general formula (I) wherein W, D, E, G, J, L, R1, R2, R3, R4, R5 and Y are as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for... Agent: Leo Pharma A/s

20110190284 - Aerosol formulations for the inhalation of beta-agonists: e

20110190283 - Fab i inhibitors: Compounds of the Formula (I) are disclosed which are Fab I inhibitors and are useful in the treatment of bacterial infections.... Agent:

20110190285 - Methods of treating a botulinum toxin related condition in a subject: The present invention provides methods of treating a botulinum toxin related condition in a subject. In certain embodiments, the methods involve administering a compound of the following formulas: (I), (II), (III), (IV), (V).... Agent: Absolute Science, Inc.

20110190286 - Therapeutically active cyclopentanes: e

20110190287 - Thrombocyte inhibition via vivo-morpholino knockdown of alpha iib: Novel compounds comprising a guanidine-rich head covalently coupled to one or more oligonucleotide antisense sequences which are useful to modulate blood coagulation by affecting the expression of integrin αIIb or β3 are described herein. This invention also includes pharmaceutical compositions containing these compounds, with or without other therapeutic agents, and... Agent: University Of North Texas

20110190288 - Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp) for use in treatment of diseases associated with a pten deficiency: wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to... Agent:

20110190289 - Imidazolothiadiazoles for use as protein kinase inhibitors: There is provided compounds of formula (I), wherein Z, M, R1, X, R2, R3 and B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein kinase (e.g. a PIM family... Agent: Centro Nacional De Investigaciones Oncologicas (cnio)

20110190290 - 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof: Provided herein are compounds according to Formula I and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancers such as colon, ovarian, pancreatic, breast, liver, prostate and hematologic cancers:... Agent: Epitherix, LLC

20110190292 - Heterobicyclic compounds useful as kinase inhibitors: o

20110190291 - Prodrug and fluoregenic compositions and methods for using the same: Methods and compositions for treating disease caused by increased iron levels are disclosed Fluoregenic compounds and methods of using the same are also described.... Agent: Regents Of The University Of California, A California Corporation

20110190293 - Quinazolinone compounds as anticancer agents: Quinazolinone compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the quinazolinone compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the quinazolinone compounds, either alone or in combination with at least one... Agent:

20110190294 - Novel estrogen receptor ligands: The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, carbamate, solvate or salt thereof, including a salt of such an ester, amide or carbamate, and a solvate of such an ester, amide, carbamate or salt. The invention also provides also provides the use of such... Agent:

20110190295 - Compositions and methods for inhibition of hepatocyte growth factor receptor c-met signaling: Derivatives and analogs of inhibitors of receptor tyrosine kinase c-Met, pharmaceutical compositions containing derivatives and analogs of c-Met inhibitors are provided. Methods of making derivatives and analogs of c-Met inhibitors and methods of use thereof are provided.... Agent: The Govt Of The U.s.a., As Rep.by The Sec.dept Of Hlth. And Human Svcs., Natl Institutes Of Health

20110190297 - Pyridine and pyrimidine based compounds as wnt signaling pathway inhibitors for the treatment of cancer: The present invention relates to pyridine and pyrimidine based compounds, pharmaceutical compositions comprising these compounds and their potential use as therapeutic agents for the treatment and/or prevention of cancer.... Agent: Cancer Research Technology Limited

20110190296 - Substituted pyrrole derivatives and their use as hmg-co inhibitors: The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as... Agent: Ranbaxy Laboratories Limited

20110190298 - 4-phenoxymethylpiperidines as modulators of gpr119 activity: The present invention provides compounds of Formula I, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent; diseases or disorders associated with the activity of GPR119.... Agent: Irm LLC

20110190299 - Thiazolidinone derivative: e

20110190300 - Amide compounds and the use thereof: The invention relates to amide compounds of Formula I: (I) and pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein: Y is CO or SOm; Z is each optionally substituted lower alkyl, lower alkenyl, cycloalkyl, aryl, heterocyclyl, etc.; R1 and R2 are each independently hydrogen, halogen, cyano, optionally substituted lower alky,... Agent:

20110190301 - Substituted cyclopentanes or cyclopentanones as therapeutic agents: Therapeutic compounds, methods, and compositions are disclosed herein for treating glaucoma and baldness in mammals. The specific compounds are described herein and are modified prostaglandin derivates.... Agent: Allergan, Inc.

20110190302 - Aryl-phenyl-sulfonamide-phenylene compounds and their use: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-phenylene compounds of the following formula (I) (collectively referred to herein as “APSAP compounds”). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both... Agent: Pimco 2664 Limited

20110190304 - Disubstituted phthalazine hedgehog pathway antagonists: The present invention provides novel 1,4-disubstituted phthalazine hedgehog pathway antagonists useful in the treatment of cancer.... Agent: Eli Lilly And Company

20110190303 - Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them: The present invention relates to novel Phosphodiesterase type 4 (PDE4) inhibitors of the formula (1) and analogs, tautomers, enantiomers, diasteromers, regioisomers, stereoisomers, polymorphs, pharmaceutically acceptable salts, appropriate N-oxides, pharmaceutically acceptable solvates thereof and the pharmaceutical compositions containing them which are useful in the treatment of allergic and inflammatory diseases including... Agent: Glenmark Pharmaceuticals S.a.

20110190307 - Assay: The present invention provides zebrafish based methods for the identification of compounds potentially useful in the treatment of motor neuron degenerative diseases (MNDDs), compounds identified by these methods and compositions, methods and medicaments for treating MNDDs.... Agent:

20110190306 - Inhibitors of plk: Compounds of formula (I) are PLK inhibitors, useful for the treatment of cell proliferative diseases: wherein R1 is hydrogen, or an optionally substituted (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl or (C3-C6)cycloalkyl group; R2 is hydrogen, or an optionally substituted (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl or (C3-C6)cycloalkyl group; R3 is hydrogen, —CN, hydroxyl, halogen, optionally substituted... Agent: Chroma Therapeutics Ltd.

20110190308 - Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents: The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to... Agent: Merck Sharp & Dohme Corp.

20110190305 - Optically pure diastereomers of 10-propargyl-10-deazaaminopterin and methods of using same: The present invention relates to diastereomers of 10-propargyl-10-deazaminopterin, compositions comprising optically pure diastereomers of 10-propargyl-10-deazaminopterin, in particular the two (R,S) diastereomers about the C10 position. Methods of preparation of these diastereomers, compositions containing them, and their use for the treatment of conditions related to inflammatory disorders and cancer are also... Agent: Allos Therapeutics, Inc.

20110190309 - Pharmaceutical product comprising a muscarinic receptor antagonist and a beta2-adrenoceptor agonist: The invention provides a pharmaceutical product, kit or composition comprising a first active ingredient which is a selected muscarinic receptor antagonist, and a second active ingredient which is a β2-adrenoceptor agonist, or use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease and asthma.... Agent:

20110190310 - Hypoxia activated drugs of nitrogen mustard alkylators: Hypoxia activated drug compounds having a structure of formula (I) are useful in the treatment of cancer and other hyperproliferative diseases.... Agent: Threshold Pharmaceuticals, Inc.

20110190312 - Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof: p

20110190311 - Use of cdk inhibitor for the treatment of glioma: The invention provides a low molecular weight ATP-competitive CDK inhibitor able to cross the blood brain barrier for use in the treatment of malignant glioma and, in particular, of glioblastoma. The compound can be administered together with one or more agents selected from the group consisting of cytotoxic or cytostatic... Agent: Nerviano Medical Sciences S.r.l.

20110190313 - Treatment of pulmonary arterial hypertension: e

20110190315 - Indoline scaffold shp-2 inhibitors and cancer treatment method:

20110190314 - Pharmaceutical compositions and their methods of use: The invention relates to a composition comprising a neuronal nicotinic receptor ligand and an α4β2 positive allosteric modulator, a method of using the same, and a related article of manufacture.... Agent: Abbott Laboratories

20110190316 - Substituted pyridines, and use thereof as gsk3 inhibitors: The invention relates to substituted pyridines and to processes for preparation thereof, and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of haematological disorders, preferably of leukopenia and neutropenia.... Agent: Bayer Schering Pharma Aktiengesellschaft

20110190318 - Pharmaceutical dosage form for immediate release of an indolinone derivative: The present invention relates to a pharmaceutical dosage form delivering an immediate release profile containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate.... Agent: Boehringer Ingelheim International Gmbh

20110190317 - Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride: The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders,... Agent:

20110190319 - Substituted heteroaryl fused derivatives as pi3k inhibitors: e

20110190320 - Compositions for treating or delaying the onset of hair loss: Disclosed herein are novel methods and compositions for treating and/or preventing hair loss in patients. Specifically exemplified herein are compositions containing a modified pyrimidine that are topically applied to a scalp of an patient. Typically, the patient has androgenic alopecia, alopecia greata, postpartum alopecia or telogen effluvium.... Agent:

20110190322 - Purin derivatives for use in the treatment of fab-related diseases: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for wound healing preferably in diabetic patients.... Agent: Boehringer Ingelheim International Gmbh

20110190323 - Cortistatin analogues and syntheses thereof: The present invention relates to analogs of cortistatin A, J, K, and L, having the general formula: I and salts thereof, wherein R1, R2, R3, R4, n, and m are as defined herein; processes for preparing such compounds and intermediates thereto; pharmaceutical compositions comprising such compounds; methods for treating a... Agent: President And Fellows Of Harvard College

20110190321 - Predictive marker for egfr inhibitor treatment: The present invention provides a biomarker that is predictive for the response to treatment with an EGFR inhibitor in cancer patients.... Agent:

20110190325 - Compounds, their syntheses, and thier uses: Embodiments of the present invention provide compounds (such as Formula (I) compounds, Formula (II) compounds, and various embodiments thereof). Compositions comprising those compounds are also provided. Methods for their preparation are included. Also, uses of the compounds are included, such as administering and treating diseases (e.g., cancer and infections).... Agent:

20110190324 - Methods of treating atherosclerosis: The present invention relates to adenosine A3 receptor antagonists and their use for the prevention and treatment of atherosclerosis by administering to a mammal, in need thereof, a therapeutically effective amount of an adenosine A3 receptor antagonist, or a pharmaceutically acceptable salt thereof, alone or in combination with other anti-atherosclerotic... Agent:

20110190326 - Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions: e

20110190328 - Acid addition salts of (3,5-bis trifluoromethyl)-n-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide:

20110190327 - Method for modulating gpr119 g protein-coupled receptor and selected compounds: A method of modulating the activity of the GPR119 G protein-coupled receptor comprising administering to a mammalian patient in need thereof a therapeutically effective amount of at least one compound of Formula I or Formula IA and, optionally, an additional therapeutic agent.... Agent: Bristol-myers Squibb Company

20110190329 - Non-amidic linkers with branched termini as cgrp receptor antagonists: The present invention is directed to novel non-amidic linkers with branched termini derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use... Agent:

20110190330 - Spirocyclic gpr40 modulators: e

20110190331 - Peripheral opioid receptor antagonists and uses thereof: The present invention provides a compound of formula I: wherein R1, R2, R2′ and X′ are as defined and described herein, methods of manufacture thereof and compositions thereof, useful for example as peripheral mu opioid receptor antagonists in treatment of side effects of opioid administration.... Agent:

20110190332 - Dopamine receptor ligands with enhanced duration of action: Trans-hexahydrobenzoaphenanthridines of the formula (I) wherein X, Y, R1, R2, R3, R4, R5, R6, and R7 are as defined herein, are disclosed. Pharmaceutical formulations including such compounds, and methods of using such compounds for treating a patient suffering from dopamine-related dysfunction of the central or peripheral nervous system are also... Agent: Effipharma

20110190333 - Dihydrotetrabenanzine for the treatment of anxiety: The invention provides a 3,11b-cis-dihydrotetrabenazine of the formula (Ib): or a pharmaceutically acceptable salt thereof for use in the prophylaxis or treatment of anxiety.... Agent: Biovail Laboratories International (barbados) S.r.l.

20110190334 - Heterocyclic sulfonamide derivatives: e

20110190336 - Azabenzimidazolones: In formula I, one member of the group (W, X, Y and Z) is a nitrogen atom and the remaining three members of the group are each independently a carbon atom covalently bonded to a radical, R4. The radicals, R1, R2, R3 and R4 are each defined herein, and n... Agent: Cara Therapeutics, Inc.

20110190335 - Nitrogenated 5-membered heterocyclic compound:

20110190337 - Substituted pyrazolopyridines, compositions containing them, method for the production thereof, and their use: The disclosure relates to substituted pyrazolo-pyridines, compositions containing them, methods for the production thereof, and to their use as medicaments, in particular, as anticancer agents.... Agent: Aventis Pharma S.a..

20110190338 - Compounds and compositions useful in the treatment of malaria: Provided herein compounds, compositions and methods useful for the treatment of malaria for a subject in need thereof, including compounds of Formula (I), Formula (II), Formula (III), Formula (IV), and Formula (V).... Agent:

20110190339 - 6-substituted isoquinolines and isoquinolinones: The invention relates to 6-substituted isoquinoline and isoquinolinone derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.... Agent: Sanofi-aventis

20110190340 - Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives: The invention relates to bi- and polycyclic substituted isoquinoline and isoquinolinones of the formula (I) wherein R1 to R12 are as defined in the application useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.... Agent: Sanofi-aventis

20110190341 - Substituted isoquinolines and isoquinolinones as rho kinase inhibitors: The invention relates to substituted isoquinoline and isoquinolinones of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.... Agent: Sanofi-aventis

20110190342 - Glycine b antagonist: The invention relates to quinoline derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.... Agent:

20110190344 - Benzimidazole modulators of vr1: e

20110190343 - Hiv-1 fusion inhibitors and methods: A new series of HIV-1 fusion inhibitors and methods of use are disclosed. The compounds are based on a substituted indole, benzimidazole, indoline or isoindoline fragment. The compounds find use in inhibiting or preventing HIV fusion from occurring, thus inhibiting or preventing entry of viral RNA into host cells. The... Agent: Touro University

20110190345 - Treatment of psychosis with a 5ht2a antagonist and a metabotropic glutamate receptor agonist or potentiator: The present invention is directed to the use of a 5-HT2A antagonist and an mGluR2/3 agonist, an mGluR2 agonist or an mGluR2 potentiator for the treatment of psychosis, including schizophrenia or bipolar disorder.... Agent:

20110190346 - Diphenyl substituted alkanes as flap inhibitors: e

20110190348 - Methods for treating cns disorders: The present invention relates to methods for treating central nervous system disorders, such as Alzheimer's disease, anxiety and major depressive disorder, by administering piperidine derivatives, e.g., 2-[4-(4-fluoro-benzyl)-piperidine-1-yl]-2-oxo-N-(2-oxo-2,3-dihydro-benzoxazol-6-yl)acetamide, and pharmaceutically acceptable salts thereof.... Agent:

20110190347 - Methods for treating neuropathic pain: The present invention relates to methods of treating diabetic neuropathic pain comprising administering piperidine derivatives, such as 2-[4-(4-fluoro-benzyl)-piperidine-1-yl]-2-oxo-N-(2-oxo-2,3-dihydro-benzoxazol-6-yl)acetamide, and pharmaceutically acceptable salts thereof. Methods of treating post-herpetic neuralgia, chronic lower back pain, osteoarthritis and acute inflammatory pain are described.... Agent: Richter Gedeon Nyrt.

20110190349 - Tetrahydro-pyran derivatives: e

20110190350 - Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit: The present invention provides methods of treating cognitive deficits associated with mental retardation. The methods comprise combining cognitive training protocols and a general administration of phosphodiesterase 4 inhibitors.... Agent:

20110190351 - Benzoimidazole derivatives and glycogen synthase kinase-3 beta inhibitors containing the same: Benzoimidazole Derivatives are provided. The compounds of the present invention are useful for Glycogen Synthase Kinase-3 Beta Inhibitors.... Agent: Oncotherapy Science, Inc.

20110190352 - Use of dabigatranetexilate for treating patients with pulmonary hypertension: The invention relates to a new use of dabigatran etexilate of formula (I), optionally in the form of the pharmaceutically acceptable salts thereof, as well as new medicament formulations which may be used for this purpose.... Agent: Boehringer Ingelheim International Gmbh

20110190353 - Fungicide hydroximoyl-tetrazole derivatives: e

20110190354 - Glycyrrhetinic acid derivative and use thereof: Disclosed is a gap junction inhibitor which is more practically useful compared with carbenoxolone. Also disclosed is a novel glycyrrhetinic acid derivative. The glycyrrhetinic acid derivative is represented by general formula (1) or (2).... Agent:

20110190355 - Heterocyclic indazole derivatives: Novel heterocyclic indazole derivatives of the formula (I), in which L, Q, R, X, Y, R3, R4 and R5 have the meanings indicated in Claim 1, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20110190356 - Compositions and methods of using (r)- pramipexole: Pharmaceutical compositions of (R)-pramipexole and one or more secondary therapeutic agents such as, for example dopamine agonists, dopaminergic agonists, COMT inhibitors, MOA inhibitors, excitatory amino acid antagonists, growth factors, neurotrophic factors, antioxidants, anti-inflammatory agents, immunomodulators, anti-glutamatergics, ion channel blockers, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists, heat shock protein inducers/protein disaggregators and... Agent: Knopp Neurosciences Inc.

20110190357 - Antimicrobial composition useful for preserving wood: Antimicrobial compositions useful for preserving wood, and comprising a variety of antimicrobial compounds.... Agent:

20110190358 - Antimicrobial composition useful for preserving wood: Antimicrobial compositions useful for preserving wood, and comprising a variety of antimicrobial compounds.... Agent:

20110190359 - Antimicrobial composition useful for preserving wood: Antimicrobial compositions useful for preserving wood, and comprising a variety of antimicrobial compounds.... Agent:

20110190360 - Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists: t

20110190361 - Tricyclic compound and pharmaceutical use thereof:

20110190362 - Antimicrobial composition useful for preserving wood: Antimicrobial compositions useful for preserving wood, and comprising a variety of antimicrobial compounds.... Agent:

20110190364 - Benzimidazole modulators of vr1: t

20110190363 - Liquid formulations of bendamustine: Stable liquid formulations of bendamustine, and pharmaceutically acceptable salts thereof, and polar aprotic solvents, are described.... Agent: Cephalon, Inc.

20110190365 - Insecticidal 4-phenyl-1h-pyrazoles: The present invention relates to novel 4-phenyl-1H-pyrazoles and their use as insecticides and/or parasiticides and also to processes for their preparation and to compositions comprising such phenylpyrazoles.... Agent: Bayer Crop Science Ag

20110190366 - Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety: The present invention relates to substituted 2-indolinone containing zinc-binding moiety based derivatives that have enhanced or unique properties as inhibitors of protein tyrosine kinase (PTK) receptors and their use in the treatment of PTK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.... Agent: Curis, Inc.

20110190367 - Novel use of 3,3'-diindolylmethane: Use of DIM and/or its derivatives for prevention, treatment and/or delay of age-related hearing loss in mammals.... Agent:

20110190368 - Organosulfur compounds, a method of making organosulfur compounds and their use for inhibiting the growth of tumour cells: Organosulfur compounds of the general formula (2) are described, wherein R1 and R2 are linear or branched C1-C5 alkyl; linear or branched C1-C5 alkenyl with the proviso that R1 is not prop-1-enyl (allyl); substituted linear or branched C1-C5 alkenyl or substituted linear or branched C1-C5 alkyl, in which the substituents... Agent: University Of Cape Town

20110190369 - Substituted pyrrole derivatives and their use as hmg-co inhibitors: The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as... Agent: Ranbaxy Laboratories Limited

20110190387 - Method for treating atherosclerosis or restenosis using microtubule stabilizing agent: The present invention is a method of preventing or reducing atherosclerosis or restenosis, and a pharmaceutical preparation used therefore. In particular, it is a method of preventing or reducing atherosclerosis or restenosis after arterial injury by treatment with a low dose of a microtubule stabilizing agent such as taxol or... Agent: The Government Of The Usa As Represented By The Secretary, Department Of Health And Human Services

20110190388 - Ursolic acid derivative and pharmaceutical composition thereof: Several ursolic acid derivatives and pharmaceutical compositions thereof are provided. The ursolic acid derivatives and the pharmaceutical compositions thereof have at least one of an anticancer and an anti-inflammatory effects. A method for increasing a reactive oxygen species in a cell is also provided. The method comprises a step of... Agent: Kaohsiung Medical University

20110190389 - Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same: Disclosed are novel oxylipins, referred to herein as docosanoids and eicosanoids, that are derived from C22 polyunsaturated fatty acids and from C20 polyunsaturated fatty acids, respectively, and methods of making and using such oxylipins. Also disclosed is the use of docosapentaenoic acid (C22:5n-6) (DPAn-6), docosapentaenoic acid (C22:5n-3) (DPAn-3), and docosatetraenoic... Agent:

20110190390 - Methods and materials for treating pancreatic cancer: This document relates to methods and materials involved in treating pancreatic cancer. For example, methods and materials for using PKCiota inhibitors to reduce pancreatic cancer cell transformed growth and invasion are provided.... Agent:

20110190391 - Ferrocene derivatives with anticancer activity: i

20110190392 - Polysaccharide based antimicrobial formulations: Described herein are antimicrobial formulations or compositions comprising an N-halogenated or N,N-dihalogenated amine compound and a saccharide-based gelling agent. Methods of using such formulations, including a method of preventing or treating an infection caused by a bacterial, a microbial, a sporal, a fungal or a viral activity, are also disclosed.... Agent:

20110190393 - Novel and efficient method for the synthesis of an amino acid: The present invention relates to a novel process for the preparation of γ-amino acids, such as (±)-3-(aminomethyl)-5-methyl-hexanoic acid (1), which is a key intermediate in the preparation of the potent anticonvulsant pregabalin, (S)-(+)-3-(aminomethyl)-5-methyl-hexanoic acid (2), and its analogues.... Agent: Generics (uk) Limited

20110190394 - Carnitine granulate and methods for its production: e

20110190395 - Novel sulphur containing lipids for use as food supplement or as medicament: The present disclosure relates to lipid compounds of general formula (I) wherein R1 is chosen from a C10-C22 alkyl group, a C10-C22 alkenyl group having 1-6 double bonds, and a C10-C22 alkynyl group having 1-6 triple bonds; R2 and R3 are the same or different and may be selected from... Agent:

20110190397 - Methods for concomitant administration of colchicine and a second active agent: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of... Agent: Mutual Pharmaceutical Company, Inc.

20110190396 - Methods for concomitant administration of colchicine and macrolide antibiotics: Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.... Agent: Mutual Pharmaceutical Company, Inc.

20110190398 - Use of immunosuppressant compounds in a new indication: A compound of formula V or formula VI for use in the treatment of a demyelinating peripheral neuropathy: wherein X is O, S, SO or SO2, R1 is halogen, trihalomethyl, OH, C1-7alkyl, C1-4alkoxy, trifluoromethoxy, phenoxy, cyclohexylmethyloxy, pyridylmethoxy, cinnamyloxy, naphthylmethoxy, phenoxymethyl, CH2—OH, CH2—CH2—OH, C1-4alkylthio, C1-4alkylsulfinyl, C1-4alkylsulfonyl, benzylthio, acetyl, nitro or cyano,... Agent: Novartis Ag

20110190399 - Curcumin nanoparticles and methods of producing the same: The present invention provides for curcumin nanoparticles and curcumin bound to chitosan nanoparticles and methods of producing the same. Bioavailability of curcumin in these formulations was shown to improve by more than 10 fold.... Agent:

20110190400 - Novel compounds for treatment of malignant tumors: The present invention comprises compounds, compositions and methods of use for sensitizing cancer cells, tumors, neoplasms, and malignancies to the effects of ionizing radiation used in the treatment of cancer. The invention further comprises a method of identifying novel radiosensitizing compounds.... Agent: The Trustees Of The University Of Pennsylvania

20110190401 - Depolymerized polysaccharide-based hydrogel adhesive and methods of use thereof: The present invention provides novel polysaccharide-based adhesive hydrogel compositions useful for wound healing and topical and transdermal delivery of therapeutic and cosmetic agents, methods of preparation and uses thereof. The hydrogel includes modified polysaccharides which bestow superior cohesion and adhesiveness to the hydrogel. The present invention further provides methods and... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem

20110190402 - Synthetic wood composite: The invention is directed a synthetic wood composite comprising biomimetic macromolecules and methods for the preparation thereof.... Agent:

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141002: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 3.12513 seconds

PATENT INFO